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    “People worry about the large number of diseases. Medical doctors worry 
about the small number of drugs.” 
                                                                                                    (3
rd
 Century B.C.) 
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1.1. Pulmonary hypertension 
 
1.1.1. Definition and classification  
 
Pulmonary hypertension (PH) is a chronic severe and fatal disease characterized by a 
sustained elevation of pulmonary artery pressure and strongly reduced exercise tolerance. 
Clinically, PH is defined as an augmentation of mean pulmonary arterial pressure of more 
than 25 mmHg at rest and/or more than 30 mmHg during exercise
1
. As a consequence, the 
right ventricular afterload increases and ultimately culminates in right ventricular failure and 
death. The new classification of pulmonary hypertension was created in Dana Point in 2008. 
(table 1) and PH is classified into 5 heterogeneous groups
2
. Although initial pathological 
events may be different in various groups, mechanisms of disease progression and 
pathological manifestations in different groups are often shared
3
.  
 
1) Pulmonary arterial hypertension (PAH)
1.1. Idiopathic PAH
1.2. Heritable (BMPR2; ALK1, endoglin (with or without hereditary hemorrhagic telangiectasia); Unknown
1.3. Drug- and toxin-induced
1.4. Associated with: Connective tissue disorders; HIV infection; Portal hypertension; Congenital heart disease;
Schistosomiasis; Chronic hemolytic anemia
1.5. Persistent pulmonary hypertension of the newborn
1´)     Pulmonary veno-occlusive (PVOD) and/or pulmonary capillary hemangiomatosis (PCH)
2) Pulmonary hypertension owing to left heart disease
2.1. Systolic dysfunction
2.2. Diastolic dysfunction
2.3. Vascular disease
3) Pulmonary hypertension owing to lung diseases and/or hypoxia
3.1. Chronic obstructive pulmonary disease
3.2. Interstitial lung disease
3.3. Other pulmonary diseases with mixed restrictive and obstructive pattern
3.4. Sleep-disordered breathing
3.5. Alveolar hypoventilation disorders
3.6. Chronic exposure to high altitude
3.7. Developmental abnormalities
4) Chronic thromboembolic pulmonary hypertension (CTEPH)
5) Pulmonary hypertension with unclear multifactorial mechanisms
5.1. Hematologic disorders: myeloproliferative disorders, splenectomy
5.2. Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis, lymphangioleiomyomatosis,
neurofibromatosis, vasculitis
5.3. Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders
5.4. Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure on dialysis
 
 
 
 
Pulmonary arterial hypertension (PAH) covers the first group in the classification of PH. This 
subcategory comprises the idiopathic PAH (earlier known as ´primary´), the heritable 
Table 1. The classification of pulmonary hypertension. 
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(familial) form and PH associated with a wide number of other conditions (table 1). PAH has 
a multi-complex pathology that includes a combination of pulmonary vascular remodelling, 
vasoconstriction, in situ thrombosis and ultimately development of right ventricular 
hypertrophy. The progressive pulmonary vascular remodelling is the attribute of PAH 
pathology and is characterized by abnormalities of vascular cells such as increased 
proliferation, migration and resistance to apoptosis
4;5
. Idiopathic PAH (IPAH) form mostly 
affects women in their third and forth decades of life. The disease is rarely diagnosed from the 
onset of clinical manifestations. As a consequence the disease is rapidly progressive and 
patients´ survival interval rate is 2-8 years from the moment of diagnosis
1
.  
 
Pulmonary hypertension owing to lung diseases and/or hypoxia covers the third group in the 
classification of PH (table 1). This group comprises many diseases or pathological conditions 
that are associated with persistent or intermittent hypoxia, either globally or regionally, within 
confined areas of the lung
6
. Chronic hypoxia may induce pathological changes in the structure 
of pulmonary arteries and finally leads to the development of remodelling and persistent 
vasoconstriction of the pulmonary circulation
6;7
.  
 
1.1.2. Clinical symptoms and diagnosis of pulmonary arterial hypertension 
 
Initial symptoms, like dyspnea and fatigue are usually nonspecific. These symptoms, together 
with chest pain, syncope and peripheral edema characterize advanced stage of disease when 
heart is already unable to adapt to the progressive increase in pulmonary vascular 
resistance
1;8
. Non-invasive echocardiography is a very useful diagnostic approach for 
diagnosis of PAH in patients and can provide important information about the parameters 
related with right heart hypertrophy (such as right ventricular dimensions and right ventricular 
wall thickness) and can help to estimate the hemodynamic parameters (such as pulmonary 
arterial pressure)
1
. Additionally to that, many other non-invasive tests can be included: 6 
minutes walking test, chest radiography, perfusion lung scanning or computer tomography 
scanning. Although these approaches provide important information about the disease, for the 
final diagnosis of PAH the right heart catheterization should be performed. The right heart 
catheterization, although invasive approach, still remains the gold standard for the diagnosis 
of pulmonary hypertension
1;9
.  
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1.1.3. Vasoconstriction and pathomorphological changes of pulmonary arteries in PAH 
 
PAH is a complex pulmonary vascular disease with a plethora of different pathophysiological, 
molecular and histopathological events. An imbalance between vasodilators and 
vasoconstrictors strongly characterize this disease
10
. The patients suffering from PAH have 
reduced levels of vasodilator and anti-proliferative agents, such as nitric oxide (NO) and 
prostacyclin, while the production of vasoconstrictors, such as endothelin-1, angiotensin II 
and thromboxane, is a noticeably augmented
10-13
. Additionally to vasoconstriction, the disease 
is associated and characterized with complex and progressive morphological changes of all 
structural layers of the pulmonary arteries. The progressive pulmonary vascular remodelling 
is the attribute and hallmark of PAH pathology and is a consequence of abnormalities in 
vascular cells, such as increased proliferation and resistance to apoptosis
4;5;14
. The 
remodelling process mostly affects the small pulmonary arteries and arterioles where the 
neomuscularization of peripheral normally non-muscularized vessels occurs
10;15
. The 
development of complex histopathological features, such as neointima and plexiform lesions 
(photographies 1), adventitial proliferation and in situ thrombosis, also takes a place in 
pathology of PAH
10;15;16
.  
 
A B C
D E F
 
 
 
 
 
 Photographies 1. Morphological changes of pulmonary arteries in PAH. Lung tissues from 
healthy donors (A, D) and patients with IPAH (B, C, E, F) were stained with Elastica van 
Gieson (A, B, C) and immunostained for detection of media layer (α-smooth muscle actin 
(violet)) and von Willebrand factor as a marker for endothelium (brown) (D, E, F). Black arrow 
indicates the neointima formation and red arrow indicates the plexiform lesions formation. 
Scale = 20µm. Photomicrographs are done by author and Ewa Bieniek.  
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Neomuscularization of normally non-muscularized distal pulmonary arteries is associated 
with increased proliferation of vascular smooth muscle cells and consequently the thickening 
of media layer
10;15;16
. The proliferation and hypertrophy of medial smooth muscle cells in the 
proximal muscular arteries also take a place in pathogenesis of PAH. Additionally to the 
changes in the media layer, there is proliferation of fibroblasts in adventitia along with 
collagen deposition
15;17
.  
 
Neointima is a typical pathomorphological formation in patients with PAH and represents a 
novel structural layer localized between the vascular endothelium and lamina elastica 
interna
10;15
. Neointima layer is composed of vascular cells and extracellular matrix. The 
accumulating body of evidence suggests that proliferating vascular cells from the media and 
adventitia of arteries migrate to the sub-endothelial space. As the neointima formation shows 
positive staining for α-smooth muscle actin, it is supposed that the present cells in this novel 
layer may represent a specialized subpopulation of smooth muscle cells
18
. However, the exact 
origin of the cells that create the neointima is not known. The fibroblasts can also migrate into 
the media and transform into smooth muscle cells
19
. On the other side, the endothelial cells 
can differentiate into smooth muscle cells when stimulated with platelet derived growth factor 
(PDGF)
20
. 
 
Plexiform lesions are another important structural feature of the pulmonary hypertension 
pathology and are found in 80% of PAH cases
15
. The disorganized proliferation of endothelial 
cells leads to the development of plexiform lesions
15
. These formations are characterized by a 
small neovessels, arising from the arteries. The cells that are involved in creation of plexiform 
lesions are endothelial cells, supported by stroma containing matrix proteins and 
myofibroblasts that express α-smooth muscle actin15;21. 
 
1.1.4. In situ thrombosis and inflammation in pulmonary hypertension 
 
In situ thrombosis is another important finding in pulmonary vessels from patients with PAH. 
It can contribute significantly to the progression and prognosis of the disease
22
. The different 
coagulation and fibrinolytic abnormalities are found in plasma samples from patients with 
pulmonary hypertension, such as increased levels of fibrinolytic inhibitor plasminogen 
activator 1 and decreased levels of a soluble thrombomodulin
23
.  
 
Introduction                                                                                                                               8 
 
An accumulating body of evidence implicates the role of inflammation in pathogenesis of 
pulmonary hypertension
24;25
. The augmented levels of inflammatory cell infiltrates 
(macrophages, mast cells, T and B lymphocytes and dendritic cells) are found in remodelled 
pulmonary vessels
25;26
. Upon pathological stimulation these cells release a plethora of 
different mediators that may contribute to the pulmonary vascular remodelling process.  
 
1.1.5. Current treatment options 
 
The pulmonary hypertension pathogenesis and pathology are the subjects of intensive 
research, but the precise mechanisms of the disease are not fully understood and successful 
therapeutic strategy to cure the disease is still needed
27
. During the years many different 
therapeutic options were investigating for the treatment of pulmonary hypertension, such as  
phosphodiesterase (PDE)-5 inhibitors (sildenafil), prostacyclin analogs (treprostinil, iloprost 
and beraprost) and endothelin-receptor antagonists (bosentan, sitaxentan)
27-31
. Although these 
therapeutic approaches importantly improved the quality of life and prolonged survival of the 
patients with pulmonary hypertension, a novel clinical options to achieve the ultimate goal of 
reversing the progressive pulmonary vascular remodelling and right ventricular hypertrophy 
are more than needed. 
 
1.2. Animal models of pulmonary hypertension 
 
1.2.1. The hypoxic animal model of pulmonary hypertension 
 
The pathological changes associated with high altitude disease in cows (Brisket disease) were 
described almost one hundred years ago by the work of George Glover and Issac Newsom. In 
1946. Ulf von Euler and Goran Liljestrand found that the reduction of the alveolar oxygen 
pressure provokes strong pulmonary arterial vasoconstriction. A short exposure to hypoxia 
leads to acute pulmonary vasoconstriction, while prolonged (chronic) exposure induces many 
different pathological events additionally to vasoconstriction (production of vascular 
endothelial growth factors, decrease of apoptosis, activation of hypoxia-inducible factor 
(HIF)-1α) that finally result in development of pulmonary vascular remodelling7. Hypoxic 
exposure of mice and rats are well accepted models of pulmonary hypertension. The chronic 
hypoxia is induced either by normal air at hypobaric pressure or oxygen-poor air at normal 
pressure. Hypoxia-induced pulmonary hypertension in rats and mice is characterized by de 
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novo muscularization of small, normally non-muscular arteries, elevation of pulmonary 
arterial pressure and development of right ventricular hypertrophy
32;33
. Although in both 
species the alterations caused by hypoxia are similar, the remodelling process and 
hemodynamic changes in rats are more severe than in mice
6;34
. As every other animal model 
of human disease, the hypoxic model also has a several limitations. In contrast to human 
situation where the patients do not respond to oxygen therapy, the hypoxia-induced 
pulmonary hypertension in mice and rats is reversible after return the animals to normoxic 
conditions. Additionally to that, this model is not associated with the development of 
neointima or plexiform lesion formation that strongly characterize the human disease. 
However, it was shown recently that hypoxia in combination with vascular endothelial growth 
factor receptor (VEGFR)-2 inhibitor SU5416 injection in rats leads to development of 
pulmonary vascular changes like neointima and this model may be more relevant with human 
situation 
35;36
.  
 
1.2.2. Monocrotaline (MCT) animal model of pulmonary hypertension 
 
A pyrrolizidine alkaloid monocrotaline (MCT), the main toxic substance extracted from the 
plant Crotalaria spectabilis, is often used to induce experimental pulmonary hypertension and 
this model was introduced in 1961
37
. Upon a single injection of MCT, usually at the dose of 
60mg/kg, the severe pulmonary vascular disease is developed in experimental animals. 
Although this model was very frequently in use for many years and decades, the basic 
mechanism that underlies the pulmonary hypertension induction by MCT is still not fully 
understood. It is well accepted that MCT is not intrinsically toxic, but it must be activated by 
hepatic cytochrome P450 3A. The cytochrome P450 3A activates the MCT pyrrolizidine 
alkaloid to the reactive MCT pyrrole, which is the initial dehydrogenation product of 
MCT
38;39
. The initial and early target of MCT intoxication is pulmonary vascular endothelium 
that also plays a central role in human pulmonary hypertension
40
. The injury of vascular 
endothelium is followed by the extravascular leakage of proteases that react on the 
components of extracellular matrix. These pathological events are followed by the triggering 
of early inflammatory response
41
. After that the phase of increased reactivity to 
vasoconstrictors occurs and subsequently leads to the progressive thickening of the media 
layer of pulmonary arteries. Finally, these underlying mechanisms result in progressive 
elevation of pulmonary arterial pressure and right ventricular systolic pressure, and ultimate 
development of right ventricular hypertrophy.  
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Different animal species react differently to MCT injection. Some animals, for example mice, 
are resistant to MCT intoxication and do not develop pulmonary hypertension
42
. The most 
accepted and widely used animals for MCT-induced pulmonary hypertension are rats.  
 
Although some features of human pathology (neointima and plexiform lesions) are not 
covered by this model, some other important pathological characteristics, such as initial 
endothelial injury, increased perivascular inflammation and de novo muscularization of small 
pulmonary arteries are shared features between human disease and MCT animal model. These 
facts clearly suggest this model as a useful tool not only for the investigation of the 
mechanisms of the disease, but also for the discovery and evaluation of a novel therapeutic 
strategies to cure this severe and life-threatening disease. Recently it was found that 
combination of MCT injection and one-sided pneumonectomy causes the development of 
neointima and vascular obliteration of small pulmonary arterioles, suggesting this improved 
MCT model for future use as it reproduces these important morphological features of human 
disease
16
.  
 
1.3. RhoA and Rho-kinase (ROCK) signalling 
 
The small GTPase RhoA is one of the members of the Rho (Ras homologous) protein family 
that regulate cellular functions such as contraction, motility, proliferation and apoptosis, and 
Rho-kinases (ROCKs) are the best characterized downstream targets for RhoA
43
. In general, 
RhoA act can be considered as a molecular switch that cycles between an inactive GDP-
bound and an active GTP-bound molecular conformation that interacts with downstream 
effectors to induce a certain cellular response
44
.  
 
GTP-bound active form of RhoA translocates to the plasma membrane and activates its 
targets, including the two isoforms of the serine/threonine Rho-kinase (ROCK): ROCK-1 and 
ROCK-2
45-48
. ROCK protein structure comprises a kinase (catalytic) domain (CATS) located 
at the amino (N)-terminus of protein, followed by a coiled-coil region that contains Rho-
binding domain (RB) and pleckstrin-homology domain (PH)
44
. The C-terminal region of 
ROCKs has a function as a negative regulatory region responsible for autoinhibition of the 
ROCKs activity in resting cells, probably via interaction with the catalytic part of the 
molecule
49
. The activation of ROCKs can be done by binding of the active GTP-bound RhoA 
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to RB domain (scheme 1)
44
. Additionally, ROCKs can be activated also by a lipid messengers 
such as arachidonic acid. 
                                                    
 
 
 
 
 
Both ROCK isoforms are ubiquitously expressed in tissues including vasculature and heart
50
. 
Owing to its role in key cell functions, hyperactive ROCK signalling results in cardiovascular 
disorders associated with sustained abnormal vasoconstriction and promotion of vascular 
remodelling
44;48
. 
 
1.4. Role of Rho-kinase in pulmonary hypertension 
 
Abnormally activated Rho-kinase (ROCK) signalling may be involved in the 
pathomorphological changes in all three layers of pulmonary arteries (scheme 2)
51
. 
Hyperactive ROCKs may affect the intima layer of pulmonary vessels and cause the 
endothelial dysfunction, decreased nitric oxide (NO) production and increased inflammatory 
cell migration. Also, ROCK signalling may be involved in pathological events related to the 
media layer, such as increased proliferation, migration and resistance to apoptosis of smooth 
muscle cells and induction of vasoconstriction. Finally, augmented Rho-kinase activity may 
contribute to the increase of inflammatory cell migration and of vasa vasorum in adventitia of 
pulmonary arteries
48;51
.  
 
Rho-kinase is significantly involved in contraction, differentiation, proliferation and migration 
of pulmonary vascular smooth muscle cells
44;51
. 
 Scheme 1. RhoA activated Rho-kinase – molecular structure. Legend: 
PH – pleckstrin-homology domain; RB – RhoA binding domain; G – GTP; 
CATS – catalytic domain; AA – arachidonic acid. 
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Rho-kinase plays an important role in smooth muscle cell (SMC) contraction and it is 
suggested from the literature that this signalling is one of the most important regulators of 
vascular tone
52
. The major regulatory mechanism of SMC contraction is 
phosphorylation/dephosphorylation of myosin-light chain (MLC)
44;53
. Active Rho-kinase 
phosphorylates MLC and translates it from inactive to active form that further induces the 
smooth muscle contraction
44;54
. Additionally to that, active Rho-kinase phosphorylates 
myosin-phosphatase (MYPT) and inactivates it. Inactivation of MYPT prevents the active 
MYPT-mediated dephosphorylation of MLC and its subsequent deactivation
54
. Thus, Rho-
kinase and MYPT co-ordinately regulate the phosphorylation state of MLC (scheme 2´).  
 
Scheme 2. Roles of Rho-kinase in pulmonary hypertension. The possible involvement of 
Rho-kinase in different pathological events related to the development of pulmonary 
hypertension. ( ) – increase or ( ) – decrease of a specific event. Modified from Fukumoto 
et al, 2007. 
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Rho-kinase also plays a role in vascular smooth muscle cell (VSMC) proliferation (scheme 3). 
Rho-kinase participate in platelet-derived growth factor (PDGF)-BB-induced activation of 
extracellular-regulated kinase ½ (ERK ½) and proliferation of VSMCs
55
. Additionally, it was 
found that VSMC proliferation induced by thrombin and urotensin-II is inhibited by Rho-
kinase blockers, suggesting an involvement of Rho-kinase in G-protein-coupled receptor-
stimulated cell proliferation
56;57
. Also, active Rho-kinase downregulates cyclin-dependent 
kinase inhibitor p27
Kip1
 expression and subsequently accelerates the cell cycle 
progression
58;59
. 
 
The literature suggests the role of Rho-kinase in VSMC migration process. It was found that 
blockade of Rho-kinase leads to inhibition of VSMCs migration induced by PDGF and 
 Scheme 2´. Rho-kinase function in vasoconstriction/vasorelaxation processes. Legend: 
CATS – catalytic domain; RB – RhoA binding domain; PH - pleckstrin-homology domain; 
G – GTP; AA – arachidonic acid; MBS – myosin-binding subunit. 
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lysophosphatidic acid
60
. Additionally, Rho-kinase inhibition blocks the UTP- and thrombin-
induced SMCs migration
61;62
. 
 
 
 
 
 
Accumulating body of evidence incriminates the role of Rho-kinase in endothelial cell 
functions. ROCK is involved in the regulation of endothelial permeability via Rho-kinase-
dependent regulation of actin cytoskeleton organization and cellular contractility. ROCK also 
activates LIM-kinase 1, which is responsible for thrombin-induced endothelial barrier 
disrupction involved microtubule disassembly
44;63;64
. Additionally and importantly, it was 
found that Rho-kinase negatively regulates NO production by endothelial cells, suggesting the 
contribution of ROCK in disturbing the balance of NO/endothelial NO synthase (eNOS) 
system
65-67
. 
 
1.5. Inhibition of Rho-kinase as a strategy for the treatment of pulmonary hypertension 
 
A plethora of different studies on animal models of pulmonary hypertension, such as chronic 
hypoxia-, MCT-, vascular endothelial growth factor receptor inhibition and chronic hypoxia-, 
pneumonectomy and MCT- and bleomycin-induced pulmonary hypertension suggest that 
increased ROCK expression and activity is involved in the pathogenesis of this disease
68-75
. 
Moreover, accumulating data clearly implicate ROCK signalling in clinical pulmonary 
 Scheme 3. Rho-kinase signalling. Rho-kinase involvement in different cellular processes. 
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hypertension and suggest that ROCK inhibition provides beneficial acute effects in patients 
suffering from this severe and life-threatening disease
76-82
. 
 
Fasudil and Y-27632 are two most commonly investigated ROCK inhibitors
83;84
. These 
inhibitors have been used to evaluate and establish the role of Rho-kinase in the pulmonary 
hypertension pathology
75;85
. It was shown in vivo that Fasudil significantly reduced the MCT-
induced pulmonary hypertension in rats and inhibited the development of pulmonary 
hypertension in chronic hypoxia mice, suggesting Rho-kinase as a promising target for the 
treatment
68;69
. 
 
Although Fasudil exerts the beneficial effects, the data obtained with this compound should 
be interpreted with caution because it is also a relatively potent inhibitor of other kinases, for 
example protein kinase C
86
. Additionally to that, ROCK inhibitors show the discrepancy in 
their efficacy depending on the dose, route of administration and animal model, suggesting 
the importance and need to find more potent and selective Rho-kinase inhibitor
48
.  
 
1.6. Azaindole-based Rho-kinase inhibition 
 
Recently, a highly selective and orally active azaindole-based ROCK inhibitor, azaindole-1 
(6-chloro-N
4
-{3,5-difluoro-4-[(3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}pyrimidi-       
ne-2,4-diamine) has been reported (scheme 4)
87;88
. This novel ROCK inhibitor acts in an 
ATP-competitive manner with activity in the lower nanomolar range (half maximum 
inhibitory concentration (IC50) of 0.6nM and 1.1nM for human ROCK-1 and ROCK-2, 
respectively), suggesting that this inhibitor is a very potent compound
87
. 
 
                                    
 
 
   Scheme 4. Structural chemical formula of azaindole-1. 
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Importantly, although ATP-competitive, azaindole-1 was inactive against 89 of different 
kinases and exhibited only a weak activity against 21 kinases, suggesting that this compound 
is a highly selective ROCK inhibitor
87
.  
 
Moreover, oral administration of azaindole-1 induces a dose-dependent decrease in blood 
pressure without inducing a significant reflex increase in heart rate of normotensive and 
spontaneously hypertensive rats
87
. However, the therapeutic potential of azaindole-1 in animal 
models of pulmonary hypertension has not yet been investigated. 
 
1.7. Aims of the study 
 
The aims of this study were to investigate the effects of a novel Rho-kinase inhibitor 
azaindole-1 on: 
1) acute hypoxic pulmonary vasoconstriction (HPV) in isolated, ventilated and buffer-
perfused mice lungs 
2) proliferation of rat pulmonary arterial smooth muscle cells (PASMCs) in vitro 
3) hemodynamics, right ventricular hypertrophy and pulmonary vascular remodelling in 
experimental pulmonary hypertension induced by MCT-injection in rats 
4) hemodynamics, right ventricular hypertrophy and pulmonary vascular remodelling in 
experimental pulmonary hypertension induced by chronic hypoxic exposure in mice 
5) pulmonary vascular cell proliferation in situ by immunohistochemistry of the lungs of 
MCT-injected rats for proliferating cell nuclear antigen (PCNA) 
6) Rho-kinase activity by immunohistochemistry of the lungs of MCT-injected rats for 
phospho-myosin phosphatase target subunit 1 (p-MYPT1). 
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2.1. MATHERIALS 
 
2.1.1. Substances and reagents 
Animal experiments 
Monocrotaline (Crotaline®)                       Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Sodium-hydroxide 1N (1mol/l)                                                      Merck, Darmstadt, Germany 
Chlorhidric acid 1N (1mol/l)                                                          Merck, Darmstadt, Germany 
Enrofloxacine (Baytril 2.5%®)                                  Bayer Vital GmbH, Leverkusen, Germany 
Isoflurane                                           Baxter Deutschland GmbH, Unterschleissheim, Germany 
Transcutol (32230)                                     Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
(Diethylene glycol monoethyl ether) 
Cremophor (Cremophor®, 95921)             Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Distilled water                                                    B.Braun Melsungen AG, Melsungen, Germany 
Fasudil (H139)                                           Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Y-27632 (Y0503)                                       Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Azaindole-1                                                           BayerHealth Care AG, Wuppertal, Germany 
Ketamin-hydrochloride (100 mg/ml) (Ketavet®)               Pharmacia GmbH, Berlin, Germany 
Medetomidin-hydrochloride (1mg/ml) (Domitor®)                   Pfizer GmbH, Berlin, Germany 
Povidone-iodine solution (Braunoderm®)         B.Braun Melsungen AG, Melsungen, Germany 
Physiological saline solution (0.9% NaCl)         B.Braun Melsungen AG, Melsungen, Germany 
Heparin (Heparin-Natrium-25.000-ratiopharm®)                Ratiopharm GmbH, Ulm, Germany 
Formaline (Formaldehyd-Lösung 3.5-3.7%)          Otto Fischar GmbH&Co.KG, Saarbrücken,   
                                                                                                                                        Germany                                                                                                                                            
- Specific reagents for transmitter implantation 
Bepanthen crème                                                                            Bayer, Leverkusen, Germany 
Antisedan                                                                                    Pfizer GmbH, Berlin, Germany 
Anticoagulant gel                                        Dataquest A.R.T.2.1. Data Sciences Inc., MN, USA 
- Specific reagents for catheterization of rats and mice 
Ventilation gas (50%O2, 50% N2)                                                  Air Liquid, Siegen, Germany 
Rompun 2% (Xylazin-hydrochloride)                                            Bayer, Leverkusen, Germany 
- Specific reagents for isolated murine lungs 
Dimethyl-sulfoxide (DMSO)                     Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Krebs-Henseleit electrolyte solution                                 Serag-Wiessner KG, Naila, Germany 
Pentobarbital sodium (100 mg/kg)                               Merial GmbH, Hallbergmoos, Germany 
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Normoxic ventilation gas                                                  Air Liquide, Ludwigshafen, Germany 
(21% O2, 5.3% CO2, balanced with N2) 
Hypoxic ventilation gas                                                     Air Liquide, Ludwigshafen, Germany 
(1% O2, 5.3% CO2, balanced with N2)  
Cell culture 
DMEM/F12 medium                                                                Invitrogen, Darmstadt, Germany 
Fetal calf serum (FCS, 0.1% and 10%)                 PAA Laboratories GmbH, Pasching, Austria 
DMSO                                                        Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
HBSS                                                                                      Gibco BRL, Eggenstein, Germany 
3-4,5-dimethylthiatol-2,5 diphenyl tetrabromide (MTT)           Promega, Mannheim, Germany    
(CellTiter 96AQ kit)                                                                                   
Methyl-
3
H-Thymidine                                               Amersham Biosciences, Munich, Germany 
Trichloroacetic acid (TCA)                        Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
0.1M NaOH                                                Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Histology 
Paraffin embedding medium (Paraplast Plus®)         Sigma-Aldrich Chemie GmbH, Steinheim,   
                                                                                                                                        Germany                                                                                                                                           
Sodium-chloride                                                     Carl Roth GmbH&Co, Karlsruhe, Germany 
Potassium-chloride                                                 Carl Roth GmbH&Co, Karlsruhe, Germany 
Disodiumhydrogenphosphat dihydrat (Na2HPO4·2H20)                 Merck, Darmstadt, 
Germany 
Potassiumdihydrogenphosphat (KH2PO4)                                      Merck, Darmstadt, Germany 
Roti-Histol (Xylol) (Roti®-Histol)                         Carl Roth GmbH&Co, Karlsruhe, Germany 
Ethanol 70%, 96%, 99.6%                      Otto Fischar GmbH&Co.KG, Saarbrücken, Germany 
Isopropyl-alcohol (99.8%)                         Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Mounting medium (Pertex®)                                                Medite GmbH, Burgdorf, Germany 
- Specific reagents for medial wall thickness determination 
Resorcin-Fuchsin                                                   Waldeck GmbH&co.KG, Münster, Germany 
Nuclear Fast Red (Kernechtrot Aluminiumsulfat)                 Waldeck GmbH&co.KG, Münster,   
                                                                                                                                        Germany 
- Specific reagents for degree of muscularization assessment 
Methanol                                                    Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Hydrogen-peroxide (50%)                                                              Merck, Darmstadt, Germany 
Trypsin (Digest All2®)                                        Invitrogen Corporation, Camarillo, CA, USA 
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Normal Horse Serum                                                  Alexis Biochemicals, Grünberg, Germany 
Streptavidin-Biotin-Blocking Kit                                     Lunaris Biologische Produkte GmbH,   
                                                                                                      Wertheim-Bettingen, Germany 
Vectastain ABC Kit                        Lunaris Biologische Produkte GmbH, Wertheim-Bettingen,  
                                                                                                                                        Germany 
Horseradish peroxidase streptavidin                       Vector Laboratories, Burlingame, CA, USA 
Vector VIP (Vector®VIP substrate Kit for peroxidise SK-4600)               Vector Laboratories,    
                                                                                                                   Burlingame, CA, USA 
DAB (substrate Kit for peroxidase SK-4100)         Vector Laboratories, Burlingame, CA, USA 
Methyl-green (H-3402)                                           Vector Laboratories, Burlingame, CA, USA 
- Specific reagents for in situ proliferation and Rho-kinase activity assessments 
Citrate buffer                                            Zymed Laboratories Inc., Invitrogen, Carlsbad, USA 
Methanol                                                    Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Hydrogen-peroxide (50%)                                                              Merck, Darmstadt, Germany 
Proteinase K  (Dako Real
TM
, Proteinase K (40x)         Dako Denmark A/S, Glostrup, Denmark 
Proteinase K diluent (Dako Real
 TM
, Proteinase K diluent)                          Dako Denmark A/S,  
                                                                                                                        Glostrup, Denmark 
Peroxidase (ImmPress
TM
 Reagent Kit)                             Lunaris Biologische Produkte GmbH,   
                                                                                                      Wertheim-Bettingen, Germany 
Nova RED Substrate (Vector® Nova RED
TM
                  Lunaris Biologische Produkte GmbH, 
Substrate Kit for Peroxidase)                                                       Wertheim-Bettingen, Germany 
Hematoxylin (Hematoxylin QS H-3404)                Vector Laboratories, Burlingame, CA, USA 
- Antibodies used for immunohistochemistry 
 Anti-α-smooth muscle actin antibody                                Sigma-Aldrich, Steinheim, Germany 
(Monoclonal, mouse anti-human)  
Anti-von Willebrand factor antibody                             Dako Cytomation, Hamburg, Germany 
(Polyclonal, rabbit anti-human) 
Anti-PCNA antibody                                      Santa Cruz Biotechnology, Santa Cruz, CA, USA 
(Polyclonal, rabbit) 
Anti-p-MYPT1 antibody                                Santa Cruz Biotechnology, Santa Cruz, CA, USA 
(Polyclonal, goat) 
 
2.1.2. Consumables 
Animal experiments 
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Gloves (Nitra-Tex®)                                                   Ansell Ltd., Tamworth, Staffordshire, UK 
Napkins                                                                                              Tork, Mannheim, Germany 
Needles (BD Microlance 3®) (18G /1.2mm x 40mm),                       Becton Dickinson GmbH, 
20G (0.9mm x 40mm), 26G (0.45mm x 13mm)                                        Heidelberg, Germany 
Syringes (Injekt®-F) (1ml, 2ml, 5ml, 20ml)      B.Braun Melsungen AG, Melsungen, Germany 
Black thread no.16                                                                Coats GmbH, Kenzingen, Germany 
Medical adhesive bands 2.5cm/9.2m                                   3M Health Care, St.Paul, MN, USA 
(3M™ Durapore™ Surgical Tape)   
Gauze 4x5 cm  (Purzellin®)                                Lohmann und Rauscher, Rengsdorf, Germany 
Gauze balls size 6, unsteril                       Fuhrmann Verrbandstoffe GmbH, Munich, Germany 
Surgical instruments                                       Fine Science Tools GmbH, Heidelberg, Germany  
                                                                               Martin Medizintechnik, Tuttlingen, Germany 
Cannula for vein catheter support 22G               B.Braun Melsungen AG, Melsungen, Germany 
(Vasocan Braunüle®) 
Instrument for venous catheterization                B.Braun Melsungen AG, Melsungen, Germany 
(Intradyn ™ Venous Hemostasis Introducer) 
Silicone catheter for right heart catheterization                                                      Custom-made 
Polyethylene cannula for insertion into the carotid artery                     B.Braun Melsungen AG,  
(Vasofix® Safety®, 22G)                                                                           Melsungen, Germany 
Tracheal cannula                             Custom-made from BD Microlance 3® 15 or 20G  needles             
                                                                       (Becton Dickinson, Germany) shortened to 1.5cm 
Stopcock for infusion therapy and pressure monitoring                        B.Braun Melsungen AG,   
(Discofix® C-3)                                                                                          Melsungen, Germany 
Rat restrainer (model 81)                                IITC Life Science Inc., Woodland Hills, CA, USA 
Heating underlay (ThermoLux®)                            Witte + Sutor GmbH, Murrhardt, Germany 
Eppendorf tubes (Microtubes 1.5ml)                                          Sarstedt, Nürnbrecht, Germany 
Scalpels (Feather Disposable Scalpel)                 Feather Safety Razor Co, LTD, Osaka, Japan 
Cell culture 
Gloves (Nitra-Tex®)                                                   Ansell Ltd., Tamworth, Staffordshire, UK 
Tissue Culture Dish                                     Greiner Bio-One GmbH, Frickenhausen, Germany 
Tissue Culture Flask                                    Greiner Bio-One GmbH, Frickenhausen, Germany 
Tissue Culture 6-well Plate                          Greiner Bio-One GmbH, Frickenhausen, Germany 
Histology 
Gloves (Nitra-Tex®)                                                   Ansell Ltd., Tamworth, Staffordshire, UK 
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Histological glass slides 25x75x1mm                      R. Langenbrinck, Emmendingen, Germany 
(SuperFrost UltraPlus®) 
Embedding cassettes                                                    Leica Microsystems, Nussloch, Germany 
Coverslips 24x36mm                                     Menzel GmbH&Co.KG, Braunschweig, Germany 
Microtom blades  (Microtome blade type A35)      Feather Safety Razor Co Ltd, Osaka, Japan 
Tips for automatic pipettes 200μl, 1000μl, 10μl                         Sarstedt, Nürnbrecht, Germany 
Automatic pipettes 10-100μl, 1-10μl                                   Eppendorf AG, Hamburg, Germany 
(Eppendorf PhysioCare concept) 
 
2.1.3. Systems and machines 
Animal experiments 
Weighing machine for animals                                   August Sauter GmbH, Albstadt- Ebingen,  
(Sauter RP 3000)                                                                             Bayer Leverkusen, Germany 
Balance for substances (Mettler Toledo PB303 Delta Range®)      Mettler Toledo, Switzerland 
Transducers                                                        B.Braun Melsungen AG, Melsungen, Germany 
(Combitrans Monitoring Set Mod.II for Arterial Blood Pressure Management) 
Ventilation system for rats                             IITH Life Science Inc., Woodland Hills, CA, USA 
(SAR- 830/P Ventilator) 
Computer and screen 
Blood analyzer (Rapidlab™ 348)                                  Bayer Healthcare, Fernwald, Germany 
Centrifuge                                     Hettich-Zentrifugen GmbH & Co. KG, Tuttlingen, Germany 
(Hettich Mikro 200R) 
O2 controller (Model 4010)                                                          Labotect, Göttingen, Germany 
Peristaltic pump (REGLO Digital MS-4/12)                    Ismatech SA, Glattbrugg, Switzerland 
Piston pump Minivent Type 845                 Hugo Sachs Elektronik Harvard Apparatus GmbH,    
                                                                                                        March-Hugstetten, Germany 
Analog-to-digital transformer PCLD                                     Advantech, Feldkirchen, Germany 
Force Transducer                                       Hottinger Baldwin Messtechnik, Fuchstal, Germany 
DSI Receiver                                               Dataquest A.R.T.2.1. Data Sciences Inc., MN, USA 
DSI Matrix                                                   Dataquest A.R.T.2.1. Data Sciences Inc., MN, USA 
DSI software                                                Dataquest A.R.T.2.1. Data Sciences Inc., MN, USA 
Transmitter (TA 11PA-C40)                       Dataquest A.R.T.2.1. Data Sciences Inc., MN, USA 
Cell culture 
β-counter                                                                   Canberra Packard, Central Europe GmbH  
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Spectrophotometer                                                                     Eppendorf, Hamburg, Germany 
Cell culture incubator                                                             Heraeus GmbH, Hanau, Germany 
Cell culture microscope                                                Helmut Hund GmbH, Wetzlar, Germany 
Counter plate reader                                                                 TECAN, Mainz-Kastel, Germany 
Culture Hood                                                                          Heraeus GmbH, Hanau, Germany                                                                                                                   
Histology 
Tissue dehydrating machine                             Leica Microsystems, Nussloch GmbH, Germany 
(Leica TP 1050) 
Tissue embedding machine                              Leica Microsystems, Nussloch GmbH, Germany 
(Leica EG 1140 H) 
Cooling table (Leica EG 1150 C)                    Leica Microsystems, Nussloch GmbH, Germany 
Automated microtome (Leica RM 2165)         Leica Microsystems, Nussloch GmbH, Germany 
Flattening table (Leica HI 1220)                      Leica Microsystems, Nussloch GmbH, Germany 
Flattening bath for paraffin sections                Leica Microsystems, Nussloch GmbH, Germany 
(Leica HI 1210) 
Computer (Q 550 IW)                                      Leica Microsystems, Nussloch GmbH, Germany 
Software (Q Win V3)                                       Leica Microsystems, Nussloch GmbH, Germany 
Light microscope (DMLA)                              Leica Microsystems, Nussloch GmbH, Germany 
Ice flake machine (Icematic F100 Compact)                       Castelmac SPA, Castelfranco, Italy 
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2.2. METHODS 
  
2.2.1. Experimental animals   
Adult male Sprague-Dawley rats (Species: Rattus norvegicus) (300-350g of body weight 
(BW)) and C57BL/6 mice (Species: Mus musculus) (20-22g BW) were obtained from Charles 
River Laboratories, Sulzfeld, Germany. Rats and mice were kept under controlled temperature 
conditions (~22ºC), with food and water provided ad libitum. All studies were performed 
according to the guidelines of the University of Giessen and were approved by the local 
authorities. 
                                                         
2.2.2. Monocrotaline (MCT)-induced pulmonary hypertension model in rats 
A pyrrolizidine alkaloid monocrotaline (MCT), the main toxic substance extracted from the 
plant Crotalaria spectabilis is often used to induce experimental pulmonary 
hypertension
70;89;90
. Pulmonary hypertension in this study was induced in adult male Sprague-
Dawley rats of 300 to 350g of BW via single subcutaneous administration of monocrotaline 
(dose: 60mg/kg) in the area of animal neck. Monocrotaline solution was freshly prepared by 
dissolving the alkaloid in 1N HCl and 1N NaOH. In details, 250mg of monocrotaline was 
dissolved in 3ml of 1N HCl and 2ml of 1N NaOH and pH was adjusted at 7.4. An injection 
was administered at day 0, after light inhalation anesthesia with isoflurane. Healthy control 
rats received only 500µl of saline solution subcutaneously under the same conditions. To 
avoid unwanted infections, rats were receiving an antibiotic solution (2.5% baytril) from day 
1 to 15 upon MCT injection. Baytril was dissolved in the drinking water, at a concentration of 
2ml of baytril in 500ml of water.  
 
2.2.3. Chronic hypoxia-induced pulmonary hypertension model in mice 
Pulmonary hypertension in C57BL/6 mice was induced by chronic hypoxic (Hox) exposure 
(10% O2)
70;89-91
. The animals were kept in ventilated hypoxic chambers under the temperature 
range from 22-24°C (photography 2). The constant level of hypoxia was held by an 
autoregulatory control unit (model 4010). The humidity in the system was prevented by 
condensation in a cooling system and CO2 was removing by soda lime. Mice exposed to 
normoxia (Nox) conditions (21% O2) in a ventilated chamber served as a healthy control. 
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2.2.4. Isolated murine lungs   
The technique of successive hypoxic maneuvers was employed in isolated, ventilated and 
buffer-perfused mice lungs to investigate the effect of different Rho-kinase (ROCK) inhibitors 
(azaindole-1, fasudil and Y-27632) on acute hypoxic pulmonary vasoconstriction (HPV)
70;92
. 
The technique of mouse lung isolation was performed as previously described (scheme 5)
93-95
. 
Mice were initially anesthetized intraperitoneally with pentobarbital sodium at the dose of 
100mg/kg of BW and injected intravenously with heparin to prevent the coagulation. A 
median cut was made in the center of mice neck and the trachea was exposed by blunt 
dissection and was partially transected. After that mice were intubated and ventilated by room 
air with a specific piston pump (Minivert Type 845). Then the midsternal thoracotomy was 
performed, the ribs were spread followed by the incision of the apical part of the heart. The 
right ventricle was cut and a fluid-filled perfusion catheter was forwarded into pulmonary 
artery. After catheter insertion, the perfusion (REGLO Digital MS-4/12) with sterile and ice-
cold Krebs-Henseleit solution was started at 4°C and a flow of 0.2ml/min. The composition of 
Krebs-Henseleit solution is depicted below (table 2). 
 
    Photography 2.  Hypoxic chamber. 
 
Matherials and methods                                                                                                            26 
 
               
5%Hydroxyethylamylopectin
13.32mMGlucose
1.3mMMagnesium chloride
2.4mMCalcium chloride
1.1mMPotassium dihydrogen
phosphate
4.3mMPotassium chloride
120mMSodium chloride
 
 
 
 
In parallel, the ventilation was changed from room air to a normoxic gas mixture of 21% O2, 
5.3% CO2 balanced with N2. Without interruption of ventilation and perfusion, the lungs, 
trachea and heart were excised from the thorax and were freely suspended from a force 
transducer to monitor lung weight gain. The second perfusion catheter was inserted via the 
left ventricle into the left atrium and the flow was increased from 0.2 to 2ml/min. The lungs 
were then washed with buffer to remove the blood and perfusion system was closed for 
recirculation. The left atrial pressure was set at 2mmHg and the system of isolated, ventilated 
and perfused lungs was placed in a temperature-equilibrated chamber and was heated to 
37.5°C. The pulmonary arterial pressure was registered by pressure transducers connected to 
the perfusion catheters and were digitised with an analog-to-digital converter
95
. The ROCK 
inhibitors were prepared freshly in dimethyl-sulfoxide (DMSO). Sequential hypoxic 
maneuvers of 10 min duration interrupted by 15 min periods of normoxia were performed. 
The effect of the Rho-kinase inhibitors on pressure responses provoked by alveolar hypoxia 
(1% O2, 5.3% CO2 and balanced N2 gas mixture) was determined within such a sequence of 
repetitive hypoxic maneuvers. The Rho-kinase inhibitors were added to the buffer fluid 5 min 
after a hypoxic challenge, with the addition starting after the second hypoxic maneuver was 
accomplished. Cumulative dose effect curves were established by addition of the inhibitors 
(dose range: 0.1-30.0µM). Controls received the vehicle (DMSO) only
70
. 
Table 2.  The composition of Krebs-Henseleit solution. 
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AMP
REC
PT FT
PT
IC
IC
BT
PT
T
PC
PA
LV
IC
RP
R
V
PEEP
GN GH
Lung
                        
 
 
 
 
 
 
 
 
2.2.5. Cell culture (proliferation and cytotoxicity assays)  
The isolation, culture and proliferation assay of primary pulmonary artery smooth muscle 
cells (PASMCs) were done as described in the literature
70;89
. The cells were isolated from 
Scheme 5. Isolated, ventilated and perfused mouse lung system. AMP-amplifier, BT-
bubble trap, FT-force transducer, GN-normoxic gas, GH-hypoxic gas, IC-intraluminal 
catheter, LV-left ventricle, PA-pulmonary artery, PC-perfusion catheter, PEEP-positive 
end-expiratory pressure, PT-pressure transducer, R-reservoir, RP-roller pump, REC-
recording device, T-trachea, V-ventilator. Modified from Seeger W. et al (1994). 
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healthy and monocrotaline-injected rats (day 21, n = 3) and cultures were maintained at 37°C 
in a humidified 5% CO2 - 95% O2 atmosphere. Equal number of PASMCs (~ 4x10
4
 
cells/well) was seeded and the following day the medium was substituted with DMEM/F12 
containing 0.1% fetal calf serum (FCS) to render the cells quiescent. After 24h serum 
starvation, cells were induced to cell cycle re-entry by FCS (10 %) together with different 
concentrations of ROCK inhibitors (fasudil, Y-27632 and azaindole-1 (500, 1000 and 
5000nM in DMSO)) for 24h, including in the last 12h the incorporation of [
3
H]-thymidine 
(1.5μCi/ml). Cells were then washed twice with 500μl chilled HBSS, fixed with 250μl ice-
cold methanol and precipitated by 250μl 10% trichloroacetic acid (TCA). Finally samples 
were lysed in 0.1M NaOH and transferred to 4ml scintillation solution and counted by a β-
counter. The values are expressed as disintegration per minute (dpm). All the experiments 
were done in triplicate. Cell viability/cytotoxicity was assessed by the MTT assay using a 
CellTiter 96AQ kit (Promega) according to the manufacturer´s instructions. The cells were 
plated in 96-well plates and allowed to attach for 6h, and then cultured under serum-free 
conditions with various concentrations of fasudil, Y-27632 and azaindole-1 for 48h. The 
number of surviving cells was determined by measuring the absorbance at 560nm (A560 nm) 
of the dissolved formazan product after addition of 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt for 1 hour. All of the 
experiments were carried out in triplicate
70
. 
 
2.2.6. Radio-telemetry study  
To investigate the effects of azaindole-1 on progressive elevation of right ventricular systolic 
pressure (RVSP) and on heart rate (HR), the online radio-telemetry measurement (Dataquest 
A.R.T. 2.1; Data Sciences Inc.) was performed as described previously
90;96;97
. A catheter 
connected to a fluid filled sensor (transmitter) was inserted into the jugular vein and 
forwarded to the right ventricle (RV) of rats under anesthesia. To anesthetize the animals the 
combination of ketamine and domitor was used in the ratio of 10 : 1 (v/v). The transmitter 
was placed under the skin in the area of animal back. The signal from the transmitter (model 
TA11PA-C40) was transferred to a remote receiver and a data-exchange matrix connected to 
a computer (scheme 6b). The top of the telemetry catheter was filled up with anticoagulant gel 
to avoid the blood coagulation. The waveform was displayed on the computer and used to 
ensure correct positioning of the catheter. After the surgery the animals received a light dose 
of anti-anesthetic (antisedan) to wake up easier and for the next 2 weeks were receiving 
antibiotic baytril to reduce the unwanted infections due to surgery. Animals were allowed to 
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recover for 3 to 4 days before the induction of pulmonary hypertension by monocrotaline and 
were housed individually in standard rat cages. Monocrotaline (MCT)-injected rats were 
randomized into two groups and they received either azaindole-1 or placebo from day 21 for 
two weeks. Azaindole-1 was prepared daily in transcutol-based vehicle. Briefly, the 
compound was dissolved in a special vehicle (the mixture of transcutol, cremophor and 
distilled water in the ratio of 10 : 20 : 70 (v/v/v)) to reach the wanted dose. Rats were treated 
by oral gavage at the dose of 10 mg/kg BW/day. The placebo group received only vehicle. 
RVSP and HR were recorded once per day in duration of 10 minute over the next 35 days 
from the time of MCT injection. The dose of azaindole-1 was selected based on literature and 
our own pilot experiments
87
. 
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2.2.7. Chronic treatment study – experimental design  
To investigate the therapeutic efficacy of azaindole-1 in animal models of pulmonary 
hypertension (PH), chronic treatment studies were performed. The MCT-rats (n=30) were 
randomized into two groups and treated orally by gavage from 21 to 35 days either with 
azaindole-1 (dose: 10mg/kg BW/day) or placebo (a transcutol-based vehicle). Saline injected 
rats served as healthy control (n=10). Mice exposed to chronic hypoxia (n=16) were treated 
daily with azaindole-1 (dose: 30mg/kg BW/day) or placebo from 21 to 35 days. As 
Scheme 6. Online telemetry system for monitoring hemodynamics and heart rate. (a) 
Transmitter surgical implantation. 1 – transmitter, 2 – right jugular vein, 3 – fluid-filled 
catheter, 4 – heart. (b) Radio-telemetry system. 1 – transmitter; 2 – the animal with inserted 
transmitter/catheter complex placed on 3 – receiver; 4 – matrix; 5 – software for data analysis 
(Data Sciences Inc., MN, USA). 
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mentioned, the dose of azaindole-1 was selected based on literature and our own pilot 
experiments and prepared daily for oral application
87
. Control mice (n=6) remained under 
normoxia (21% O2). At the end of experiment (day 35 of the MCT-injection in rats or chronic 
hypoxic exposure of mice) the animals were sacrificed for hemodynamic and right ventricular 
hypertrophy measurements. The experimental protocol is depicted below (scheme 7). 
 
 
21 35Days
Healthy controls/Normoxia
MCT/Hypoxia
MCT/Hypoxia
Vehicle
Azaindole-1
MCT injection/Hypoxia
 
 
 
 
 
2.2.8. Hemodynamic and right ventricular hypertrophy (RVH) measurements  
Right ventricular systolic pressure (RVSP) was measured by a catheter inserted into the right 
ventricle (RV) via the right jugular vein and for systemic arterial pressure (SAP) the left 
carotid artery cannulation was performed as described
70;89;90
. Rats were initially anesthetized 
by intraperitoneal injection with combination of ketamine and domitor solutions in the 
volume ratio of 10:1. After that the tracheotomy was performed and animals were artificially 
ventilated with a mixture of oxygen and nitrogen (1:1), at a constant frequence of 60 
breaths/min, with an inspiratory flow rate of 500 – 600cc/min. The inspiratory time was 0.5 
seconds and the positive end expiratory pressure (PEEP) was set to 1cmH2O. The left carotid 
artery was isolated and cannulated for the measurement of SAP. A cannula was connected to 
a fluid-filled force transducer. The right heart catheterization was performed for measurement 
of RVSP. The right jugular vein was isolated and the home-made silicone catheter was 
connected to a fluid-filled force transducer. The catheter was inserted into the jugular vein and 
Scheme 7. Chronic treatment study – experimental design. 
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forwarded into the right ventricle under the guidance of pressure tracing. To prevent the blood 
coagulation a volume of 1ml of heparin solution was administered through the jugular vein. 
The fluid force transducers were calibrated at 0 to the hillum level before the beginning of 
experiment. The Labtech Notebook Runtime Version 9.02 computer software was recording 
the ventilation pressure, SAP and RVSP for 5 – 10 minutes. Hemodynamic changes in mice 
were measured similarly as for the rats with small modifications. Mice were anesthetized with 
combination of ketamine, rompun and saline in the volume ratio of 1:1:2. Before receiving the 
anesthesia the mice were injected with heparin to reduce the effect of blood coagulation. Mice 
were tracheotomised and artificially ventilated. The rest of the procedure was the same as for 
the rats. At the end of experiments, the hearts of both animal models were extracted and 
dissected to separate right ventricle (RV) from left ventricle plus septum (LV+S), and the 
weight ratio RV/(LV+S) was calculated as a measurement of right ventricular hypertrophy 
(RVH) (scheme 8). 
 
 
                                                   
1                   2
 
 
 
 
 
 
 
 
 
2.2.9. Measurements of cardiac output and total systemic and pulmonary vascular 
resistance 
After hemodynamic measurements the rat blood was collected from jugular vein and carotid 
artery.  Hemoglobin (Hb), arterial and venous saturation were measured by blood gas analyzer 
(Rapid lab
TM
 348). Cardiac output was calculated using the Fick principle, by employing the 
mixed venous oxygen and the arterial oxygen content as previously described
98
. Cardiac index 
Scheme 8. Right heart hypertrophy measurements. The heart ratio was 
determined as the weight ratio of right ventricle (1) and left ventricle plus 
septum (2). 
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(CI) was assessed as a cardiac output normalized to body weight (BW) of rats. Total 
pulmonary resistance (TPR) was determined by dividing RVSP with CI, while total systemic 
resistance was assessed by dividing SAP with CI. The detailed formulas with measure units 
are presented in the table 3
99
. 
 
TSR (mmHg·100 g BW·min / ml) = SAP / CI
TPR (mmHg·100 g BW ·min / ml) = RVSP / CI
CI (ml/min·100 g BW) = CO·100/BW
CO (ml/min) = 5.46/ ((Hb·arterial saturation·0.0134) – (Hb·venous saturation·0.0134))
 
 
 
 
 
 
 
 
 
2.2.10. Lung tissue processing 
After the hemodynamic measurement and collection of the blood samples, the abdomen and 
thoracic cavity were opened and the both heart ventricles were incised in order to allow the 
removal of blood
89
. The right ventricle was incised at approximately 5mm below the base of 
pulmonary artery. The lungs were flushed out of blood at a pressure of 30cmH2O above the 
pulmonary hillum by a cannula inserted into the pulmonary artery through the right ventricle 
and connected to a reservoir filled with saline solution. The left lungs were prepared for 
histology using a cannula inserted into the pulmonary artery and connected to a reservoir 
filled with 3.5-3.7% formalin solution. The left lung was perfused at a pressure of 30cmH2O 
above the pulmonary hillum for 5 to 10 minutes, further isolated and stored in formalin 
Table 3. Formulas for calculating the cardiac output (CO), cardiac index (CI), total 
pulmonary resistance (TPR) and total systemic resistance (TSR). Legends: Hb – 
hemoglobin; BW – body weight; RVSP – right ventricular systolic pressure; SAP – systemic 
arterial pressure. 
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solution at 4ºC over night and then in phosphate buffer (PBS, pH=7.4). After that the lungs 
were placed in histological cassettes, dehydrated in an automatic dehydration machine and 
then embedded in paraffin (scheme 9). Sections of 3μm in diameter were cut from the paraffin 
blocks using a microtome. 
 
          
1 2
 
 
 
 
 
2.2.11. Histology and pulmonary vascular morphometry  
In general, the assessment of pulmonary vascular remodelling was done by determination of 
the degree of muscularization of the rats and mice small peripheral pulmonary arteries. Intra-
acinar arteries in rats and mice were analyzed by categorizing them as fully muscular, 
partially muscular and non-muscular. In addition, the medial wall thickness of the vessels was 
analyzed as another well-known parameter for determination of pulmonary vascular 
remodelling
70;89;90
. All analyses were done in a blinded fashion. 
Medial wall thickness. After dehydration and paraffin embedding, a 3 µm sections were 
stained for Elastin - Nuclear Fast Red to assess the medial wall thickness, as described 
previously
70;89
. Medial wall thickness was defined as the distance between the lamina elastica 
interna and lamina elastica externa. Percentage of medial wall thickness (% MWT) was 
examined by light microscopy using a computerized morphometric system (Qwin, Leica, 
Wetzlar, Germany) and was calculated by a formula:  
                       
% MWT = (2·wall thickness/external diameter)·100 
 
Degree of muscularization. A 3 μm sections of formalin-fixed and paraffin embedded lung 
tissues were obtained and double immunostaining was performed with an anti-α-smooth 
Scheme 9. Lung tissue processing. 1 – embedding machine, 2 – microtome. 
Matherials and methods                                                                                                            35 
 
muscle actin antibody (αSMA) (dilution 1:900, clone 1A4, Sigma, Saint Louis, Missouri) and 
anti-human von Willebrand factor antibody (vWF, dilution 1:900, Dako, Hamburg, 
Germany), as described previously
89;90;100
. The sections were initially maintained for 60 
minutes at 58-60˚C in the heating chamber. After that the sections were deparaffinized in 
xylol and progressively rehydrated in a graded ethanol series. The endogenous peroxidase 
activity was blocked by using a freshly prepared solution of hydrogen peroxide (H2O2) in 
methanol in the volume ratio of 1:1. Similarly, the endogenous biotin and streptavidine were 
eliminated by using a specific biotin/streptavidine blocking solutions. Antigen retrieval was 
performed by treatment with trypsin for 10 minutes at 37°C. For staining of pulmonary 
vascular smooth muscle layer and endothelium, the slides were first incubated with normal 
horse serum for 30 minutes to avoid the non-specific bindings caused by immunoglobulin 
cross-reactivity and after that incubated with primary antibodies. For vascular smooth muscle 
staining the slides were incubated with anti-α-smooth muscle actin primary antibody at room 
temperature. To detect the vascular endothelium the slides were incubated with anti-von 
Willebrand factor primary antibody at 37°C. Both antibodies were diluted 1:900 in 10% BSA 
and maintained for 30 minutes. After that the slides were washed a couple of times with 
phosphate-buffered saline (PBS, pH 7.4) and further incubated with the corresponding 
biotinylated secondary antibodies. The composition of PBS buffer is depicted below (table 4). 
                 
900mlDistilled water
2gKH2PO4
11.5gNa2HPO4x2H2O
2gKCL
80gNaCl
 
 
 
Two different substrates were used to develop a colour by reaction with horseradish 
peroxidise/streptavidine complex coupled to the secondary antibodies: VIP substrate 
   Table 4. The composition of PBS buffer. 
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determined the purple/violet colour of the smooth muscle layer and DAB determined the 
brown colour of the vascular endothelium. Finally, the sections were counterstained with 
methyl-green, then progressively dehydrated, coverslipped using mounting medium and 
examined by light microscopy using a computerized morphometric system (Qwin, Leica, 
Wetzlar, Germany). For monocrotaline-induced pulmonary hypertension rat model the vessels 
of 20-50µm in size were used for analysis. For hypoxia-induced pulmonary hypertension 
mice model the vessels of 20-70µm in size were used for analysis. Each vessel was 
categorized as non-muscularized (N), partially muscularized (P) or fully muscularized (F). 
The percentage of pulmonary vessels in each category was determined by dividing the 
number of vessels in that category with the total number counted in the same experimental 
group. 
 
2.2.12. Immunohistochemistry for phospho-myosin phosphatase target subunit 1 (p-
MYPT1) and proliferating cell nuclear antigen (PCNA)  
Paraffin-embedded lung tissue sections with thickness of 3µm were deparaffinized in xylol 
and rehydrated in a graded ethanol series to PBS. Antigen retrieval was performed by pressure 
cooking in citrate buffer (pH 6.0). The sections were pretreated with hydrogen peroxide 
(15%) to quench endogenous peroxidase activity. Following blocking with BSA (10%) for 
one hour and then with blocking serum (Impress reagent kit, Vector Laboratories, CA) for 20 
minutes, the sections were incubated overnight at 4°C with primary antibodies. Rabbit 
polyclonal anti-PCNA and goat polyclonal anti-p-MYPT1 (Thr 696) antibodies (1: 100 and 
1:20 dilutions, respectively; Santa Cruz Biotechnology Inc.) were used as primary antibodies. 
Development of the dye was carried out with peroxidase and substrate (NovaRed substrate 
kit, Vector Laboratories, CA) according to manufacturer´s instruction (Vector laboratories, 
CA). Finally, sections were counterstained with hematoxylin (Zymed laboratory, UK) and 
coverslipped using mounting medium
70
. Additionally, the PCNA positive pulmonary vascular 
cells were counted using a light microscope throughout the entire section and the index of 
proliferation (IOP) was determined as the number of PCNA positive cells per pulmonary 
vessel. 
IOP = The number of PCNA-positive cells in the vessels/The number of the vessels
 
The IOP (in %) for placebo and azaindole-1 treated groups was calculated by assuming the 
average IOP of healthy control lungs as 100 %. 
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2.2.13. Data analysis  
All data are expressed as mean ± SEM. The different experimental groups were analyzed by 
one-way ANOVA and Newman-Keuls post-hoc test for multiple comparisons. Values of 
p<0.05 (*), p<0.01 (**) and p<0.001 (***) were considered as statistically significant. Two-
way ANOVA analysis with Bonferroni multiple comparison post-hoc test was performed to 
compare the RVSP values derived by telemetric measurement.  
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3.1. Effects of Rho-kinase inhibitors on acute hypoxic pulmonary vasoconstriction (HPV) 
First we investigated the pulmonary vasorelaxant potency of azaindole-1 and the other 
commonly used ROCK inhibitors fasudil and Y-27632. The experiment was performed with 
isolated, ventilated and buffer-perfused murine lungs as described in methods. All the ROCK 
inhibitors significantly reduced the HPV in a dose dependent manner as compared with vehicle 
control. The maximum inhibitory effects on HPV were ~75 % for fasudil and Y-27632 and ~90 
% for azaindole-1 at the highest concentration, 30μM (figure 1). The effects of fasudil and Y-
27632 were comparable; however, a clear leftward shift of the dose response curve was 
observed with azaindole-1 as compared with fasudil and Y-27632. At the higher doses (10 and 
30μM) there were significant reductions of HPV by azaindole-1 versus fasudil and Y-27632. 
The findings suggest that azaindole-1 is a potent pulmonary vasorelaxant and shows a stronger 
effects on HPV in comparison with other Rho-kinase inhibitors. 
                          
      
 
 
 
 
Figure 1. Effects of fasudil, Y-27632 and azaindole-1 on hypoxic pulmonary 
vasoconstriction (HPV). The effects of Rho-kinase inhibitors on acute HPV in isolated, 
ventilated and buffer-perfused murine lungs (n=5) were investigated as described in 
methods section. Dose-response curves are shown. Data are presented as mean ± SEM. 
**p<0.01 and ***p<0.001 versus vehicle; |p<0.05 and ||p<0.01 versus fasudil/Y-27632. 
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3.2. Effects of Rho-kinase inhibitors on cell cytotoxicity 
Then we investigated if azaindole-1 and other two Rho-kinase inhibitors show any toxic 
effects on the pulmonary arterial smooth muscle cells (PASMCs). PASMCs 
viability/cytotoxicity was assessed by the MTT assay (figure 2). We did not observe any 
cytotoxic effects of all Rho-kinase inhibitors (fasudil, Y-27632 and azaindole-1) at the 
concentrations tested in our study. 
 
 
          
a)
b)
 
 
 
 
 
 
 
Figure 2. Effects of fasudil, Y-27632 and azaindole-1 on pulmonary arterial smooth 
muscle cell (PASMC) viability. The effects of Rho-kinase inhibitors on viability of 
PASMCs isolated from healthy and MCT-injected rats were investigated using MTT assay 
as described in methods. Absorbance measured at 560nm as an estimation of the number of 
surviving PASMCs from (a) healthy and (b) MCT-injected rats is shown (n=3). Each dot 
represents mean ± SEM. ns – not statistically significant. 
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3.3. Effects of Rho-kinase inhibitors on proliferation of PASMCs isolated from healthy rats 
The effects of fasudil, Y-27632 and azaindole-1 on PASMCs proliferation were investigated 
by thymidine incorporation assay (figure 3).  There were no significant effects of various 
concentrations of the Rho-kinase inhibitors (500, 1.000 and 5.000nM) on the thymidine 
incorporation into PASMCs derived from healthy rats. 
 
c)
a)
b)
 
 
 
 
 
               
               
 
 
 
 
Figure 3. Effects of fasudil, Y-27632 and azaindole-1 on proliferation of pulmonary 
arterial smooth muscle cells (PASMCs) isolated from healthy rats. The proliferation 
assays were performed as described in methods. Effects of various concentrations of (a) 
fasudil, (b) Y-27632 and (c) azaindole-1 on thymidine incorporation into primary PASMCs 
isolated from healthy rats (n=3) are shown. Data are presented as % of FCS control. Bars 
represent mean ± SEM. 
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3.4. Effects of Rho-kinase inhibitors on proliferation of PASMCs isolated from MCT-
injected rats 
As PASMCs are phenotypically changed in disease conditions, we investigated the effect of 
azaindole-1 on proliferation of PASMCs derived from MCT-injected rats by thymidine 
incorporation assay. In each assay, fasudil and Y-27632 were also included. In PASMCs 
derived from MCT-rats, there was a tendency towards reduction in the thymidine 
incorporation by fasudil and Y-27632 at their higher concentrations; however, the reduction 
was significant only by 5000nM of Y-27632 (p<0.05 versus FCS control, figure 4b). 
Azaindole-1 reduced the thymidine incorporation significantly at all concentrations tested 
(p<0.001 versus FCS control, figure 4c). The findings suggest that azaindole-1 has more 
potent inhibitory effect on PASMC proliferation than other inhibitors.  
                 
c)
a)
b)
         
 
 
 
 
Figure 4. Effects of fasudil, Y-27632 and azaindole-1 on proliferation of pulmonary 
arterial smooth muscle cells (PASMCs) isolated from MCT-injected rats. The 
proliferation assays were performed as described in methods. Effects of various 
concentrations of (a) fasudil, (b) Y-27632 and (c) azaindole-1 on thymidine incorporation 
into primary PASMCs (n=3) are shown. Data are presented as % of FCS control. Bars 
represent mean ± SEM. ***p<0.001 versus FCS. 
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3.5. Effect of azaindole-1 on MCT-induced progressive elevation of RVSP 
To investigate the in vivo efficacy of azaindole-1, progressive elevation of RVSP was 
monitored online by telemetry technique in MCT-injected rats treated with azaindole-1. The 
RVSP at day 1 (26.5 ± 1.7 mmHg) was significantly elevated at day 21 (37.8 ± 0.9 mmHg) 
and further at day 35 (67.9 ± 4.3 mmHg) in rats receiving placebo (figure 5a). Treatment with 
azaindole-1 daily from day 21 to 35 significantly reduced RVSP (38.8 ± 2.9 mmHg at day 
35). To check if azaindole-1 induced any reflex tachycardia, we monitored the heart rate of 
the rats. We observed that the heart rates of placebo and azaindole-1 treated rats were 
comparable (figure 5b). The findings suggest that azaindole-1 has potent pulmonary 
vasorelaxant effect in vivo. 
                    
    
         
a) 
b) 
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3.6. Effects of azaindole-1 on hemodynamics in MCT-induced pulmonary hypertension 
We investigated therapeutic efficacy of azaindole-1 in MCT-induced pulmonary hypertension 
(PH) as described in methods. MCT induced a robust PH in rats receiving placebo as reflected 
by the significant increase of RVSP (72.3 ± 2.6 versus 27.2 ± 1.3 mmHg in healthy control) at 
day 35 of MCT-injection (figure 6a). Rats receiving azaindole-1 resulted in a significant 
decrease of RVSP (49.5 ± 3.7 mmHg) as compared to the placebo rats. There was no 
significant change in systemic arterial pressure (SAP) among the experimental groups (figure 
6b).  
   
a) b)
                        
 
 
 
 
 
 
Figure 5. Effect of azaindole-1 on progressive elevation of right ventricular systolic 
pressure (RVSP). The effects of azaindole-1 on progressive increase of RVSP induced by 
MCT injection in rats were investigated by radio-telemetry technique and RVSP and heart 
rate were monitored online, as described in methods. (a) RVSP and (b) heart rate are given. 
Data are presented as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001. 
 
 
Figure 6. Effect of azaindole-1 on hemodynamics in MCT-induced pulmonary 
hypertension in rats. Rats were injected with saline (healthy controls) or MCT. MCT-
injected rats were treated with azaindole-1 (MCT-Aza1) or placebo from day 21 to 35 after 
MCT injection, followed by hemodynamic measurement as described in methods. (a) Right 
ventricular systolic pressure (RVSP) and (b) systemic arterial pressure (SAP) are shown. 
Data are presented as mean ± SEM (n=10-15). ***p<0.001. 
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3.7. Effect of azaindole-1 on cardiac index and total pulmonary and systemic resistance in 
MCT-induced pulmonary hypertension (PH) 
The total pulmonary resistance (TPR) was significantly increased in MCT-injected rats 
receiving placebo (2.96 ± 0.24 mmHg·min·ml
-1
·100g BW) as compared to the healthy control 
(1.51 ± 0.15 mmHg·min·ml
-1
·100g BW) and azaindole-1 treatment reduced the TPR (2.04 ± 
0.22 mmHg·min·ml
-1
·100g BW, p<0.05 versus placebo) (figure 7a). There was no significant 
change in total systemic resistance (TSR) among the experimental groups (figures 7b). In 
addition, analysis of cardiac output showed a comparable cardiac index (CI) among the 
experimental groups (24.9 ± 4.2, 23.8 ± 1.9 and 28.8 ± 3.5 ml·min
-1
·100g BW for healthy 
control, MCT-placebo and azaindole-1 treated rats respectively) (figure 7c). 
a)
b) c)
 
 
 
 
 
 
Figure 7. Effect of azaindole-1 on cardiac index and total pulmonary and systemic 
resistance in MCT-induced pulmonary hypertension in rats. Rats were injected with 
saline (healthy controls) or MCT. MCT-injected rats were treated with azaindole-1 (MCT-
Aza1) or placebo from day 21 to 35 after MCT injection. (a) Total pulmonary resistance 
(TPR), (b) total systemic resistance (TSR) and (c) cardiac index (CI) are shown. Data are 
presented as mean ± SEM (n=10-15). *p<0.05, **p<0.01. 
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3.8. Effects of azaindole-1 on hemodynamics in chronic hypoxia-induced pulmonary 
hypertension (PH) in mice. 
Chronic hypoxia induced a PH in mice receiving placebo as reflected by significant increase 
in RVSP (33.3 ± 1.2 versus 23.3 ± 1.1 mmHg under normoxia) (figure 8a). Treatment with 
azaindole-1 significantly decreased RVSP (26.7 ± 0.8 mmHg) as compared to the hypoxic 
placebo mice. Hypoxic mice tended to have slightly decreased SAP; however, no significant 
difference was observed in SAP between placebo and azaindole-1 treated mice (68.1 ± 1.7 
and 61.0 ± 3.5 mmHg respectively) (figure 8b). 
                                
a)
b)
 
 
 
 
 
 
Figure 8. Effect of azaindole-1 on hemodynamics in chronic hypoxia-induced 
pulmonary hypertension (PH) in mice. Mice were exposed to normoxia (Nox) or 
chronic hypoxia (Hox). Hypoxic mice were treated with azaindole-1 (Hox-Aza1) or 
placebo and hemodynamic measurement was done at day 35, as described in methods. 
(a) Right ventricular systolic pressure (RVSP)  and (b) systemic arterial pressure (SAP) 
of different experimental groups are given. Data are presented as mean ± SEM (n=6-
10). ***p<0.001. 
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3.9. Effects of azaindole-1 on right ventricular (RV) hypertrophy in MCT- and chronic 
hypoxia-induced pulmonary hypertension (PH) 
We investigated RV hypertrophy by measuring RV/(LV+S) ratio and found that the increased 
RVSP was accompanied by RV hypertrophy in both MCT- and chronic hypoxia-induced PH. 
The RV/(LV+S) ratio was significantly increased in MCT-injected rats receiving placebo 
(0.48 ± 0.01) as compared to the healthy rats (0.22 ± 0.01). Treatment with azaindole-1 
significantly reduced the RV/(LV+S) ratio (0.38 ± 0.02 versus placebo) (figure 9a). Mice 
under chronic hypoxia revealed significantly higher RV/(LV+S) ratio (0.34 ± 0.01) as 
compared to the normoxic mice (0.24 ± 0.01). Treatment with azaindole-1 improved the 
chronic hypoxia-induced RV hypertrophy as reflected by significantly reduced RV/(LV+S) 
ratio (0.310 ± 0.001) (figure 9b). 
                                  
a)
b)
  
 
 
 
 
Figure 9. Effect of azaindole-1 on right ventricular hypertrophy in MCT- and chronic 
hypoxia-induced pulmonary hypertension. Rats were injected with saline (healthy control) or 
MCT. Mice were exposed to normoxia (Nox) or hypoxia (Hox). Both animal models were treated 
with azaindole-1 (MCT-Aza1 and Hox-Aza1) or placebo from day 21 for 2 weeks followed by 
right ventricular hypertrophy measurement, as described in methods. Right to left ventricular plus 
septum weight ratio (RV/(LV+S)) of (a) MCT-injected rats (n=10-15) and (b) hypoxic mice (n=6-
10) are given. Data are presented as mean ± SEM. *p<0.05, ***p<0.001. 
Results                                                                                                                                       48 
 
3.10. Effects of azaindole-1 on pulmonary vascular remodelling in MCT-induced 
pulmonary hypertension – Degree of muscularization  
The effects of azaindole-1 on pulmonary vascular remodelling were assessed by determining 
the degree of muscularization of the peripheral pulmonary arteries. MCT injection in rats 
resulted in an enhanced pulmonary artery muscularization as evident from the enhanced 
immunoreactivity for α-smooth muscle cell actin (figure 10a). Pulmonary vascular 
morphometry revealed significantly increased fully muscularized vessels (57.0 ± 1.5%) and 
decreased non-muscularized vessels (2.4 ± 0.3%) in MCT-injected rats receiving placebo 
compared with healthy controls (2.2 ± 0.8% and 42.2 ± 3.7%, respectively). Azaindole-1 
treatment significantly decreased fully muscularized vessels (18.5 ± 2.4%) (figure 10b). There 
was significantly higher proportion of partially muscularized vessels in azaindole-1-treated 
rats (73.3 ± 2.2% versus 40.6 ± 1.4% in placebo), suggesting that the treatment impaired the 
progressive muscularization by preventing the shift from partial towards full muscularization 
of the pulmonary vessels.  
             a) 
                      
A B
C D
E F
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                  b) 
                      
 
 
 
 
 
 
 
 
 
 
 
 
3.11. Effects of azaindole-1 on pulmonary vascular remodelling in MCT-induced 
pulmonary hypertension – Medial wall thickness 
The effects of azaindole-1 on pulmonary vascular remodelling were assessed also by 
determining the medial wall thickness of the peripheral pulmonary arteries. Prior to 
Figure 10. Effect of azaindole-1 on degree of muscularization in MCT-induced 
pulmonary hypertension. The rat lung sections were immunostained for von Willebrand 
factor and α-smooth muscle actin and pulmonary vascular morphometry was performed as 
described in methods. Representative photomicrographs are shown (a) (healthy controls (A, 
B), MCT-placebo (C, D) and azaindole-1 treated group (MCT-Aza1, E and F). (b) Proportion 
of non-(N), partially (P) or fully (F) muscularized vessels, as a percentage of total pulmonary 
vessel cross-section (sized 20-50µm), is given for healthy controls and MCT-injected rats 
receiving placebo and azaindole-1 (MCT-Aza1). Data are presented as mean ± SEM (n=10). 
Scale bars=20µm. ***p<0.001. 
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determination of the medial wall thickness, the rat lungs were stained with elastica (figure 
11a). There was significantly increased medial wall thickness in placebo (22.3 ± 0.9% versus 
9.7 ± 0.4% in healthy controls). Corroborating the decreased fully muscularized vessels, 
azaindole-1 significantly reduced the medial wall thickness (14.0 ± 0.6 %) (figure 11b).  
 
  a) 
                                    
A B
C D
E F
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                       b) 
                             
 
 
 
 
     
 
 
 
 
3.12. Effects of azaindole-1 on pulmonary vascular remodelling in chronic hypoxia-
induced pulmonary hypertension (PH) in mice 
The effects of azaindole-1 on pulmonary vascular remodelling were assessed by determining 
the degree of muscularization (figure 12a, A, B, C) and medial wall thickness (figure 12a, D, 
E, F) of the peripheral pulmonary arteries. In chronic hypoxic mice, the non-muscularized 
vessels were significantly decreased (4.9 ± 1.5% versus 49.3 ± 1.3% in normoxic mice), 
whereas the partially and fully muscularized vessels were significantly increased (63.5 ± 4.7% 
and 31.5 ± 3.9% versus 47.3 ± 0.5% and 3.5 ± 1.3% in normoxic mice, respectively). 
Treatment with azaindole-1 resulted in significant reduction of fully muscularized vessels (7.5 
± 1.7%) (figure 12b). As it was observed in MCT-injected rats, the proportion of partially 
muscularized arteries was higher in mice receiving azaindole-1 (80.9 ± 2.9%). Chronic 
Figure 11. Effect of azaindole-1 on medial wall thickness in MCT-induced pulmonary 
hypertension. The rat lung sections were stained with elastica and pulmonary vascular 
morphometry was performed as described in methods. Representative photomicrographs are 
shown (a) (healthy controls (A, B), MCT-placebo (C, D) and azaindole-1 treated group 
(MCT-Aza1, E and F). (b) Medial wall thickness (%) of the pulmonary vessels (sized 20-
50µm) is given for healthy controls and MCT-injected rats receiving placebo and azaindole-
1 (MCT-Aza1). Data are presented as mean ± SEM (n=10). Scale bars=20µm. ***p<0.001. 
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hypoxia resulted in significantly increased medial wall thickness (17.8 ± 0.9%) compared 
with the normoxic control mice (10.1 ± 0.3%) (figure 12c). Corroborating the decrease in 
fully muscularized vessels, the medial wall thickness was significantly reduced in azaindole-
1-treated mice (12.4 ± 0.4 %). 
a) 
 
                     b) 
                         
 
A B C 
D E F 
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                    c) 
                       
 
 
 
 
 
 
 
 
 
 
 
 
 
3.13. Effect of azaindole-1 on pulmonary vascular cell proliferation 
To confirm if the observed in vitro effect of azaindole-1 on cell proliferation was also present 
in vivo, we performed immunostaining for proliferating cell nuclear antigen (PCNA). We 
observed that immunoreactivity for PCNA was significantly increased in lung tissues from 
MCT-injected rats compared with that in healthy control rats (figure 13a). We analyzed the 
same size vessels as was used for vascular morphometry (20-50µm) to quantify the PCNA-
Figure 12. Effect of azaindole-1 on pulmonary vascular remodelling in hypoxia-induced  
pulmonary hypertension in mice. The lung sections exposed to normoxia and hypoxia were 
immunostained for von Willebrand factor and α-smooth muscle actin followed by pulmonary 
vascular morphometry as described in the methods section. (a) Representative 
photomicrographs of normoxic (Nox, A) and hypoxic mice receiving placebo (Hox, B) and 
azaindole-1 (Hox-Aza1, C) are shown. (b) Proportion of non- (N), partially (P) or fully (F) 
muscularized vessels, as a percentage of total pulmonary vessel cross-section (sized 20–70µm) 
is given. The lung sections were stained with elastica and the medial wall thickness (%) was 
determined as described in the methods section. (a) Representative photomicrographs of 
normoxic control (D) and hypoxic mice treated with placebo (E) and azaindole-1 (F) are given. 
(c) The medial wall thickness (%) of pulmonary vessels is shown. Data are presented as mean ± 
SEM (n=6–10). Scale bars=20µm. ***p<0.001. 
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positive vascular cells and express the result as Index of Proliferation (IOP). The findings 
revealed that there was higher IOP in MCT-injected rats receiving placebo (431.9 ± 7.2% 
versus 100.0 ± 25.8% in healthy control rats) (figure 13b). Corroborating the in vitro data, the 
IOP was significantly reduced in MCT-injected rats receiving azaindole-1 (184.1 ± 10.9 %). 
 
a) 
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                      b) 
                          
 
 
 
 
 
 
 
 
 
 
 
 
3.14. Effects of azaindole-1 on Rho-kinase activity 
We investigated the effects of azaindole-1 on Rho-kinase activity by employing 
immunohistochemistry for p-MYPT1. The immunoreactivity was localized in the media of 
the vessels and was strongly enhanced in the lung tissues of MCT-injected rats receiving 
placebo. There was decreased immunoreactivity in MCT-injected rats treated with azaindole-
1 (figure 14). 
 
Figure 13. Effect of azaindole-1 on pulmonary vascular cell proliferation. The pulmonary 
vascular cell proliferation was investigated in the rat lung sections by immunostaining of 
proliferating cell nuclear antigen (PCNA), as described in the methods section. Representative 
photomicrographs of PCNA (a) staining (healthy controls (A, B), monocrotaline (MCT)–
placebo (C, D) and MCT–azaindole-1 (E, F)) are shown. The PCNA-positive vascular cells 
were counted and the index of proliferation (IOP) was calculated as described in the methods 
section. (b) IOP (%) for healthy controls, MCT–placebo and MCT–azaindole-1 (MCT-Aza1) is 
given. Data are presented as mean ± SEM (n=6–8). Positive immunoreactivity is indicated by 
an arrow (brown staining); scale bar=20µm. ***p<0.001. 
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Figure 14. Effect of azaindole-1 on Rho-kinase activity. The ROCK activity was 
investigated in the rat lung sections by immunostaining phospho-myosin phosphatase target 
subunit 1 (p-MYPT1), as described in the methods section. Representative photomicrographs 
of p-MYPT1 staining (healthy controls (A, B), monocrotaline (MCT)–placebo (C, D) and 
MCT–azaindole-1 (E, F)) are shown. Positive immunoreactivity appears as reddish-brown 
staining; scale bars=20µm. 
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3.15. Effect of azaindole-1 on body weight of animals in hypoxia- and MCT-induced 
pulmonary hypertension 
Body weights of rats and mice were measured upon completion of the experiments at day 35. 
There was no significant effect on body weight of the animals associated with azaindole-1 
treatment (figure 15). 
 
                           
a)
b)
 
 
 
                
 
 
Figure 15. Effect of azaindole-1 on body weight of animals in hypoxia- and MCT-
induced pulmonary hypertension. The effects of azaindole-1 treatment on body weights (g) 
of (a) MCT-injected rats and (b) hypoxic mice are shown. Bars represent mean ± SEM. Nox 
– normoxia; Hox – hypoxia; Aza1 – azaindole-1. ***p<0.001. 
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3.16. Effect of azaindole-1 on survival in MCT-induced pulmonary hypertension 
The survival of rats was measured from day 22
 
until 35
 
day after saline (healthy control) and 
MCT-injection for all experimental groups. The survival of rats treated with azaindole-1 
(~86%) was slightly improved in comparison with MCT-placebo (75%) group (figure 16). 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Effect of azaindole-1 on survival in MCT-induced pulmonary hypertension. The 
survival was monitored each day for last two weeks of experiments and the mean values on day 
22 were considered as 100%. The survival curves (%) and different time points for healthy 
control and MCT-injected rats receiving placebo and azaindole-1 (MCT-Aza1) are given. 
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Investigation of a promising targets and development of a novel and effective therapeutic 
strategies and approaches for pulmonary hypertension has been an actively pursued research 
focus over the past 10 years. The therapeutic options available for pulmonary hypertension, 
such as phosphodiesterase (PDE)-5 inhibitors, endothelin receptor antagonists and 
prostacyclin analogs, as well as other approaches, significantly prolonged survival of the 
patients and improved the quality of their life (scheme 10)
27;28
.  
 
 
 
 
 
 
 
 
 
 
PH (NYHA II/III/IV)
Anticoagulants, Diuretics, O2
NO, Ca-CHBL
Oral treatment with
Ca-CHBL
_
_
+
Favorable responses
to therapy
Yes No
Continue treatment
with Ca-CHBL
NYHA III
NYHA IV
ET-R antagonists
or
PGL analogs
or
PDE5 inhibitor
or
ROCK inhibitors
ET-R antagonists
and/or
ROCK inhibitors
No improvements
Lung transplantation
Scheme 10. Diagnostic and treatment algorithm for pulmonary hypertension and 
potential application of ROCK inhibitors. Legend: PH – pulmonary hypertension; NYHA 
– New York Heart Association Functional Classification; NO – nitric oxide; Ca-CHBL – 
calcium channel blockers; ET-R – endothelin receptor; PGL – prostaglandin; PDE5 – 
phosphodiesterase-5; + - positive response; - - negative response. Modified from Fukumoto 
Y. et al, 2007. 
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For the treatment of pulmonary hypertension, usually the first step is to examine the acute 
pulmonary vascular response to conventional medical approach that includes O2 and NO 
inhalation, as well as calcium channel blockers (scheme 10)
51
. The positive response to NO 
inhalation is defined as more than 30% reduction in pulmonary vascular resistance
51
. 
According to positive or negative response to acute vasoreactivity tests and the severity of the 
disease (NYHA classification) the further strategy is determined. Currently the patients are 
treated with anticoagulants/vasodilators (prostacyclin, sildenafil, bosentan) as a 
monotherapeutic approach or combination of different compounds and in advanced stages of 
the disease the lung transplantation is often performed
51
. 
 
Despite the enormous progressions and advances in pulmonary hypertension therapy, there 
are still no successful options to finally cure the disease. A specific therapy for the majority of 
pulmonary hypertension patients is still lacking. Therefore, the discovery of a new therapeutic 
targets and strategies are more than needed. 
 
Animal studies suggested that Rho-kinase pathway plays an important role in the 
development and progression of pulmonary hypertension and the chronic treatment with Rho-
kinase inhibitors significantly improved this severe disorder. Additionally, the recent clinical 
investigations demonstrated the involvement of Rho-kinase in human disease and moreover, 
the acute beneficial effects of intravenous ROCK inhibitor fasudil have been shown in 
patients
77
. Therefore, the literature clearly implicates the ROCK signalling as promising target 
for the treatment of pulmonary hypertension and Fukumoto Y. et al suggested the potential 
application of Rho-kinase inhibitors in diagnostic and treatment algorithm for pulmonary 
hypertension (scheme 10)
51
. Recently, a novel azaindole-based ROCK inhibitor has been 
described
87
. Azaindole-1 acts in an ATP-competitive manner with activity in the lower 
nanomolar range, suggesting this inhibitor as a very potent compound. Importantly, although 
ATP-competitive, azaindole-1 was inactive against 89 of different kinases and exhibited only 
a weak activity against 21 kinases, suggesting this compound as a very selective ROCK 
inhibitor.  
 
However, the therapeutic efficacy of azaindole-1 has not yet been investigated in pulmonary 
hypertension. Therefore, we aimed to explore the potential therapeutic effects of azaindole-1 
in experimental models of pulmonary hypertension. 
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In general, the major findings of the present study are:  
 
1) azaindole-1 significantly inhibited acute hypoxic pulmonary vasoconstriction ex vivo and 
the proliferation of primary rat pulmonary arterial smooth muscle cells (PASMCs) in vitro;  
 
2) azaindole-1 treatment significantly improved hemodynamics, right ventricular hypertrophy 
and pulmonary vascular remodelling in MCT-injected rats and chronically hypoxic mice and  
 
3) the improvement in hemodynamics and vascular remodelling in rats was accompanied by 
an impaired ROCK activity and a decrease in proliferating cells in pulmonary vessels, as 
evident from reduced immunoreactivity for phospho-myosin phosphatase subunit 1 (p-
MYPT1) and proliferating cell nuclear antigen (PCNA)
70;101
. 
 
4.1. Rho-kinase inhibition in MCT-induced pulmonary arterial hypertension 
 
Hyperactivation of ROCKs, by inhibition of MYPT activity and increase of MLC 
phosphorylation, leads to contraction of vascular smooth muscle cells and subsequently to 
vasoconstriction
43;102
. In experimental models of pulmonary hypertension, acute inhibition of 
ROCK caused the pulmonary vasorelaxation and reduced pulmonary arterial pressure
73;74;103
. 
In agreement with literature we successfully demonstrated that azaindole-1 significantly 
impaired the MCT-induced progressive increase of RVSP in rats as monitored by online 
telemetry system. Importantly, no significant effect was observed on heart rates, suggesting 
that azaindole-1 treatment did not cause the reflex tachycardia. This finding is in line with the 
studies that investigated the role of ROCK-mediated sustained vasoconstriction in the 
pathogenesis of pulmonary hypertension
73;103-105
. As it has been shown that the ROCK 
inhibition reduced pulmonary vascular remodelling, we performed the experiments to test the 
effect of azaindole-1 on PASMCs proliferation in vitro
106-109
. We found that azaindole-1 
significantly inhibited the thymidine incorporation into primary PASMCs isolated form MCT-
injected rats, at high nanomolar to low micromolar range. In addition, the effect of azaindole-
1 was more potent in comparison with fasudil and Y-27632. Before the proliferation assays 
were performed we tested the possible toxicity of azaindole-1 by MTT assay and observed 
that this compound was not toxic on PASMCs at the tested doses. This clearly indicates that 
the reduced number of the cells was only because of the inhibited proliferation. Taken 
together, these in vivo and in vitro findings attribute potent vasorelaxant and antiproliferative 
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properties of azaindole-1 and clearly substantiate its therapeutic potential in pulmonary 
hypertension.  
 
To investigate the potential therapeutic efficacy of azainodole-1, we performed the chronic 
treatment studies in experimental pulmonary hypertension induced by MCT-injection in rats. 
We successfully demonstrated that azaindole-1 improved pulmonary hypertension, right 
ventricular hypertrophy and pulmonary vascular remodelling as evident from significantly 
reduced RVSP, TPR and RV/(LV+S) and degree of muscularization and medial wall 
thickness of peripheral pulmonary vessels (scheme 11).  
 
 
 
 
 
 
 
Scheme 11. Therapeutic effects of azaindole-1 in experimental pulmonary hypertension. 
Legend: MCT – monocrotaline; Hox – hypoxia; RVSP – right ventricular systolic pressure. 
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Importantly, the SAP did not change significantly in the treated animals. As Kast et al. 
observed the significant reduction of blood pressure in spontaneously hypertensive rats by 
azaindole-1, our findings at first glance may look contradictory to their findings
87
. First, the 
discrepancy in the findings could be explained at least in part by the differences in animal 
models used for experiments and duration of the treatment with ROCK inhibitor. The ROCK 
activity is enhanced in the systemic vasculature of spontaneously hypertensive rats
110
. 
Additionally, Kast et al. treated the normotensive rats only once and spontaneously 
hypertensive rats for 4 days and also noted that the blood pressure lowering effect in 
spontaneously hypertensive rats was gradually decreasing
87
. In our study we used another 
animal model and treated the animals for 2 weeks. As a conclusion, our results may not be 
directly comparable with data of Kast et al
87
. Notably, the sustained pulmonary ROCKs 
activity in animal models of pulmonary hypertension may underlie the pulmonary specific 
effects of a very selective ROCK inhibitors, like azaindole-1
48
. The literature sources suggest 
beneficial effects of Rho-kinase inhibition on the development of MCT-induced pulmonary 
hypertension in rats
105;109
. Our results extend these findings, demonstrating that azaindole-1 is 
therapeutically beneficial even when the treatment commences at the time the disease is 
already established and rapidly progressing.  
 
As a further support to our data, we found that azaindole-1 treatment resulted in an impaired 
ROCK activity, as determined by a significant reduction in p-MYPT1 immunoreactivity in 
MCT rat model. Additionally, in the line with our data from in vitro proliferation experiments, 
we demonstrated that azaindole-1 treatment significantly decreased the index of proliferation 
(IOP) of vascular cells in MCT-injected rat lungs, suggesting the antiproliferative effects of 
the compound not only in vitro, but in situ as well. Furthermore, azaindole-1 treatment of 
MCT-injected rats showed the improved survival as compared to the MCT rats receiving just 
a vehicle. 
 
As a summary, our results suggest that the therapeutic efficacy of ROCK inhibition by 
azaindole-1 may be associated with its vasorelaxant and antiproliferative  potency.  In the line 
with our study, Abe et al. have described an improvement of MCT-induced pulmonary 
hypertension in rats by chronic treatment with well-known ROCK inhibitor fasudil
68
. 
Although the fasudil exhibited the therapeutic efficacy in MCT rat model, Oka et al. 
suggested that there is a noticeable discrepancy in the findings depending on the dose, route 
of administration and animal models of pulmonary hypertension
48
. Importantly, fasudil was 
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used in previous studies at the doses from 30 to 100 mg/kg of body weight, while azaindole-1 
showed the successful therapeutic potency at lower dose of 10mg/kg of body weight, 
suggesting that not only the in vitro antiproliferative effects, but also the in vivo therapeutic 
effects of azaindole-1 are more potent in comparison with fasudil. 
 
The literature implicates the involvement of ROCKs in the pathology of experimental 
pulmonary hypertension induced by different stimuli
68;72;74;75
. Furthermore, Rho-kinase 
signalling plays a role in other signalling cascades than ROCK and accumulating body of 
literature suggests the beneficial effects of therapeutic strategies that involve other 
targets
71;72;78;111-113
. According to this, ROCK system may be involved in other signalling 
pathways that are implicated in the pathogenesis of pulmonary hypertension. 
 
To investigate if the ROCK inhibition by azaindole-1 may demonstrate the beneficial effects 
independently of the cause of the disease, we included in our study the hypoxia-induced 
model of pulmonary hypertension in mice. 
 
4.2. Rho-kinase inhibition in hypoxia-induced pulmonary hypertension 
 
Kast et al. found that azaindole-1 dose-dependently inhibited human ROCK-1 and ROCK-2 
in a low nanomolar range with IC50 values of 0.6nM and 1.1nM, respectively
87
. Therefore, 
azaindole-1 is more potent compound than fasudil and Y-27632, which have IC50 values in 
higher nanomolar range, of 158nM and 162nM, respectively
114
. Additionally, it has been 
shown that azaindole-1 inhibits the phenylephrine-induced contraction of rabbit saphenous 
artery in a concentration-dependent manner, suggesting the vasorelaxant efficacy of the 
compound
87
. To extend the finding to pulmonary circulation, that is more relevant for the 
studies of pulmonary hypertension, we performed the experiment with isolated, ventilated and 
buffer-perfused mice lungs. In our study, all three ROCK inhibitors (azaindole-1, fasudil and 
Y-27632) significantly reduced the acute hypoxic pulmonary vasoconstriction in isolated 
murine lungs. But importantly, the observed effect of azaindole-1 was more potent than the 
effects of fasudil and Y-27632. Taken together, our data and results from Kast et al., suggest 
that azaindole-1 is not only a highly selective and potent inhibitor of Rho-kinase, but also a 
stronger vasorelaxant than fasudil and Y-27632
87
. 
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The finding that azaindole-1 shows a vasorelaxant properties on acute hypoxia-induced 
pulmonary vasoconstriction and that the effect was more prominent than with other two 
ROCK inhibitors, prompted us to investigate the therapeutic efficacy of azaindole-1 on 
chronic hypoxia-induced pulmonary hypertension in mice. 
 
ROCK system plays a role in hypoxia induced pulmonary hypertension and ROCK inhibition 
demonstrated the beneficial therapeutic effects in this model, as suggested by the augmented 
literature sources
103;104;107;111-113
. In the line with literature, we found that oral treatment of 
hypoxic mice with azaindole-1 improved pulmonary hypertension, right ventricular 
hypertrophy and pulmonary vascular remodelling, as evident from significantly reduced 
RVSP, RV/(LV+S) and degree of muscularization and medial wall thickness of peripheral 
pulmonary vessels.  
 
Therefore, our findings indicate that the therapeutic efficacy of azaindole-1 is independent of 
the cause of the disease. 
 
4.3. Future experimental and clinical perspective of azaindole-based Rho-kinase 
inhibition 
 
Although MCT-induced pulmonary hypertension in rats and hypoxia-induced pulmonary 
hypertension in mice are well accepted animal models for the research of the pathological 
mechanisms and therapeutic strategies of this disease, they still have a certain limitations with 
regard to mimicking the human pathological events and manifestations. The improved animal 
models that more closely share some human features (neointima and plexiform lesions) were 
reported in recent years, such as combination of MCT and one-sided pneumonectomy and 
hypoxia in combination with vascular endothelial growth factor receptor (VEGFR)-2 inhibitor 
SU5416
16;35;36
. Azaindole-1 can thus be anticipated to yield therapeutic benefit in these animal 
models and can be used as a useful tool to further investigate the development of these 
complex pathohistological manifestations.  
 
Azaindole-1 with its advantages (table 5) in comparison with previously developed ROCK 
inhibitors, such as fasudil and Y-27632 may offer a potential therapeutic strategy to cure this 
severe human disease. 
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Regarding human pulmonary hypertension, the literature sources are emerging that implicate 
ROCK signalling in the disease pathogenesis and therefore this signalling pathway represents 
a potential therapeutic target
76;78;80;82
. More importantly, acute inhibition of ROCK by fasudil 
has revealed beneficial effects, as evident from reduction of pulmonary vascular resistance 
and pulmonary arterial pressure in patients with severe pulmonary hypertension
76;77;79;81
. 
 
Taken together, this study strongly suggests that azaindole-1 may represent a novel 
therapeutic approach for the treatment of pulmonary hypertension. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5. The advantages of azaindole-1 in comparison with fasudil and Y-27632. Legend: 
IC50 - half maximum inhibitory concentration; HPV – hypoxic pulmonary vasoconstriction; 
PASMCs – pulmonary artery smooth muscle cells; FCS - Fetal calf serum. 
 
 
 
 
 
Abbreviations and acronyms                                                                                                     68 
 
 
5. Abbreviations and acronyms 
 
PH                                                                               Pulmonary hypertension 
PAH                                                                Pulmonary arterial hypertension 
NO                                                                                                   Nitric oxide 
PDGF                                                                 Platelet-derived growth factor 
PDE                                                                                      Phosphodiesterase 
HIF 1α                                                           Hypoxia-inducible factor 1 alpha 
VEGFR-2                                  Vascular endothelial growth factor receptor-2 
SU5416                                                                                            Sugen 5416 
MCT                                                                                           Monocrotaline 
GTP                                                                              Guanosine triphosphate 
Rho                                                                                          Ras homologous 
ROCK                                                                                              Rho-kinase 
GDP                                                                              Guanosine diphosphate 
CATS                                                                                      Catalytic subunit 
RB                                                                                     Rho-binding domain  
PH                                                                        Pleckstrin-homology domain 
SMC                                                                                    Smooth muscle cell 
MLC                                                                                    Myosin-light chain 
MYPT                                                                               Myosin-phosphatase 
pMYPT1                                             Phospho-myosin phosphatase subunit 1 
MBS                                                                             Myosin-binding subunit 
VSMC                                                                  Vascular smooth muscle cell 
ERK                                                                   Extracellular-regulated kinase 
P27
Kip1
                                                          Cyclin-dependent kinase inhibitor 
UTP                                                                                   Uridine triphosphate 
eNOS                                                             Endothelial nitric oxide synthase 
ATP                                                                              Adenosine triphosphate  
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PASMC                                                  Pulmonary artery smooth muscle cell 
PCNA                                                            Proliferating cell nuclear antigen 
BW                                                                                                 Body weight 
HCL                                                                                     Hydrogen chloride 
NaOH                                                                                   Sodium hydroxide 
Hox                                                                                                       Hypoxia 
Nox                                                                                                     Normoxia 
HPV                                                        Hypoxic pulmonary vasoconstriction 
DMSO                                                                                 Dimethyl sulfoxide 
DMEM/F12       Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 
FCS                                                                                           Fetal calf serum 
HBSS                                                                 Hank's Balanced Salt Solution 
TCA                                                                                   Trichloroacetic acid 
MTT               3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
RVSP                                                           Right ventricular systolic pressure 
HR                                                                                                      Heart rate 
SAP                                                                           Systemic arterial pressure 
PEEP                                                              Positive end expiratory pressure 
RV                                                                                              Right ventricle 
LV+S                                                                        Left ventricle plus septum 
RVH                                                                   Right ventricular hypertrophy 
CO                                                                                              Cardiac output 
CI                                                                                                 Cardiac index 
TPR                                                                        Total pulmonary resistance 
TSR                                                                            Total systemic resistance 
Hb                                                                                                   Hemoglobin 
MWT                                                                              Medial wall thickness 
vWF                                                                                von Willebrand factor 
H2O2                                                                                    Hydrogen peroxide 
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BSA                                                                                Bovine serum albumin 
PBS                                                                           Phosphate buffered saline 
IOP                                                                                  Index of proliferation 
SEM                                                                        Standard error of the mean 
ANOVA                                                                            Analysis of variance 
αSMA                                                                     Alpha smooth muscle actin 
IC50                                                     Half maximum inhibitory concentration 
DAB                                                                               3,3' Diaminobenzidine 
VIP                                                                              Peroxidase Substrate kit 
Thr                                                                                                     Threonine 
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6. Summary 
 
 
Pulmonary hypertension (PH) is a severe chronic and life-threatening disease characterized by 
progressive augmentation of pulmonary arterial pressure that finally leads to right ventricle 
failure and death. PH has a multi-complex pathology which includes a combination of 
pulmonary vascular remodelling, vasoconstriction and in situ thrombosis. Key to the severity 
of the disease is the progressive pulmonary vascular remodelling. The progressive pulmonary 
vascular remodelling is the attribute of PH pathology and is characterized by abnormalities of 
vascular cells such as increased proliferation, migration and resistance to apoptosis. Although 
the PH pathology is the subject of intensive research the precise molecular mechanisms are 
still not fully understood and successful therapeutic strategy to cure the disease is still needed. 
 
An accumulating body of evidence incriminates Rho-kinase (ROCK) in the pathogenesis of 
PH and suggests the Rho-kinase as a promising therapeutic target. In the line with literature, 
our study aimed to investigate the therapeutic effects of a novel highly selective and orally 
active ROCK inhibitor, azaindole-1 in animal models of PH. We successfully demonstrated 
that azaindole-1 significantly inhibited hypoxic pulmonary vasoconstriction in isolated, 
ventilated and buffer-perfused murine lungs and proliferation of primary rat pulmonary artery 
smooth muscle cells in vitro. Furthermore, azaindole-1 chronic treatment improved 
hemodynamics and right ventricular hypertrophy in both experimental models of PH. 
Moreover, the medial wall thickness and muscularization of peripheral pulmonary arteries, as 
measures of pulmonary vascular remodelling, were significantly ameliorated. Finally, 
azaindole-1 treatment resulted in a decreased immunoreactivity for phospho-myosin 
phosphatase target subunit-1 (p-MYPT-1) and proliferating cell nuclear antigen (PCNA) in 
pulmonary vessels of monocrotaline-injected rats, suggesting an impaired ROCK activity and 
reduced proliferating vascular cells. 
 
In conclusion, azaindole-1 provided therapeutic benefit in experimental PH and this may be 
attributable to its potent vasorelaxant and antiproliferative effects. Thus, azaindole-1 may 
offer a useful approach for the treatment of pulmonary hypertension and may have a potential 
clinical application. 
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7. Zusammenfassung 
 
 
Pulmonaler Hochdruck (PH) ist eine schwere chronische und lebensbedrohliche Erkrankung, 
charakterisiert duch progressive Zunahme des pulmonal arteriellen Drucks, welche letztlich in 
Rechtsherzversagen und Tod endet. PH hat besitzt eine komplexe Pathologie mit der 
Kombination eines Remodelling der Pulmonalgefäße, Vasokonstriktion und in situ 
Thrombose. Der Schlüssel zu der Schwere dieser Erkrankung ist das progressiv verlaufende 
Gefäßremodelling. Dieses progressive pulmonale Gefässremodelling ist das Attribut der PH 
Pathologie und wird charakterisiert durch Abnormalitäten der Gefäßzellen, wie zB. verstärkte 
Proliferation, Migration, und Unempfindlichkeit gegenüber Apoptose. Obwohl die PH 
Pathologie Gegenstand intensiver Forschung ist, sind die genauen molekularen Mechanismen 
noch nicht vollständig verstanden. Eine erfolgreiche Therapie zur Heilung dieser schweren 
Krankheit ist noch nicht verfügbar. 
Rho-kinasen (ROCK) scheinen in der Pathologie der PH eine wichtige Rolle zu spielen und 
lassen vermuten, hier einen erfolgsversprechenden Angriffspunkt für eine mögliche Therapie 
darzustellen. 
Im Einklang mit dementsprechender Literatur, erforschen unsere Studien im Tiermodell den 
therapeutischen Effekt des hochselektiven, oral verfügbaren ROCK Inhibitors, Azaindole-1. 
Wir konnten erfolgreich zeigen, dass Azaindole-1 die Vasokonstriktion in isolierter, 
ventilierter und Puffer-perfundierter Mauslunge sowie die Proliferation von arteriellen glatten 
Muskelzellen der Ratte in vitro verminderte. Weiterhin verbesserte eine Behandlung mit 
Azaindole-1 die Hämodynamik und Rechtsherzhypertrophie in zwei Tiermodellen der PH. 
Ebenfalls kam es zu einer signifikanten Verbesserung der medialen Wandstärke sowie dem 
Muskularisierungsgrad der Pulmonalgefäße, welche als Paramater für das vaskuläre 
Remodelling gelten. Letztlich führte eine Behandlung mit Azaindole-1 zu einer Abnahme der 
Immunreaktivität der Phospho-Myosin Phosphatase Target Subunit-1 (p-MYPT-1) und 
PCNA (prolferating cell nuklear antigen) in Pulmonalgefäßen  der mit Monocrotalin  
injizierten Ratten, was auf eine geminderte ROCK Aktivität und reduzierte Anzahl 
proliferierender Gefäßzellen schließen lässt. 
Zusammenfassend lässt sich sagen, dass Azaindole-1 ein vielversprechender  Ansatz für die 
Behandlung experimenteller PH darstellt, was sich wahrscheinlich auf seine potenten 
vasorelaxierenden und antiproliferierenden Effekte zurückführen lässt. Dadurch könnte 
Azaindole-1 einen guten Therapieansatz für die Behandlung des pulmonalen Hochdrucks 
darstellen und das Potential für eine klinische Anwendung besitzen. 
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